BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J 2017;49:1700214. [PMID: 28182564 DOI: 10.1183/13993003.00214-2017] [Cited by in Crossref: 343] [Cited by in F6Publishing: 396] [Article Influence: 68.6] [Reference Citation Analysis]
Number Citing Articles
1 Gagatek S, Wijnant SRA, Ställberg B, Lisspers K, Brusselle G, Zhou X, Hasselgren M, Montgomeryi S, Sundhj J, Janson C, Emilsson Ö, Lahousse L, Malinovschi A. Validation of Clinical COPD Phenotypes for Prognosis of Long-Term Mortality in Swedish and Dutch Cohorts. COPD 2022;19:330-8. [PMID: 36074400 DOI: 10.1080/15412555.2022.2039608] [Reference Citation Analysis]
2 Zhang Z, Chen S, Li Q, Li D, Li Y, Xie X, Yuan L, Lin Z, Lin F, Wei X, Fang Y, Wang J, Lu W, Lajunen TK. Gene Expression Trajectories from Normal Nonsmokers to COPD Smokers and Disease Progression Discriminant Modeling in Response to Cigarette Smoking. Disease Markers 2022;2022:1-16. [DOI: 10.1155/2022/9354286] [Reference Citation Analysis]
3 Rosso A, Egervall K, Elmståhl S. Annual decline rate in FEV1s in community-dwelling older adults diagnosed with mild to moderate COPD. NPJ Prim Care Respir Med 2022;32:30. [PMID: 36028513 DOI: 10.1038/s41533-022-00292-w] [Reference Citation Analysis]
4 Li DY, Chen L, Miao SY, Zhou M, Wu JH, Sun SW, Liu LL, Qi C, Xiong XZ. Inducible Costimulator-C-X-C Motif Chemokine Receptor 3 Signaling is Involved in Chronic Obstructive Pulmonary Disease Pathogenesis. Int J Chron Obstruct Pulmon Dis 2022;17:1847-61. [PMID: 35991707 DOI: 10.2147/COPD.S371801] [Reference Citation Analysis]
5 Laiman V, Lee Y, Hou Y, Fang Y, Chen Y, Lo Y, Heriyanto DS, Lan S, Chen C, Chen X, Lee K, Chang J, Chuang H. Reduction of Emphysema Severity by Human Umbilical Cord-Derived Mesenchymal Stem Cells in Mice. IJMS 2022;23:8906. [DOI: 10.3390/ijms23168906] [Reference Citation Analysis]
6 Suissa S, Dell'aniello S, Ernst P. . COPD 2022;Volume 17:1975-86. [DOI: 10.2147/copd.s378486] [Reference Citation Analysis]
7 Kitajima T, Marumo S, Amimoto H, Shiraishi Y, Yamaki H, Shirata M, Inoue D, Fukui M. Relationship Between Episodic Nocturnal Hypercapnia and History of Exacerbations in Patients with Advanced Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2022;17:1553-63. [PMID: 35832833 DOI: 10.2147/COPD.S361914] [Reference Citation Analysis]
8 Aiello M, Marchi L, Ferrarotti I, Frizzelli A, Pisi R, Calzetta L, Manari G, Pelà G, Russo A, Minerba R, Aloe R, Ranzieri S, Corradi M, Chetta A. Distribution of the Clinical Manifestations of Alpha 1 Antitrypsin Deficiency in Respiratory Outpatients from an Area of Northern Italy. Respiration 2022;:1-8. [PMID: 35793662 DOI: 10.1159/000525549] [Reference Citation Analysis]
9 Alter P, Kahnert K, Trudzinski FC, Bals R, Watz H, Speicher T, Söhler S, Andreas S, Welte T, Rabe KF, Wouters EF, Sassmann-schweda A, Wirtz H, Ficker JH, Vogelmeier CF, Jörres RA. Disease Progression and Age as Factors Underlying Multimorbidity in Patients with COPD: Results from COSYCONET. COPD 2022;Volume 17:1703-13. [DOI: 10.2147/copd.s364812] [Reference Citation Analysis]
10 Fischer C, Jörres RA, Alter P, Trudzinski FC, Yildirim Ö, Bals R, Vogelmeier CF, Kauffmann-guerrero D, Behr J, Watz H, Holle R, Kahnert K. Basic Determinants of Disease Knowledge in COPD Patients: Results from COSYCONET. PPA 2022;Volume 16:1759-70. [DOI: 10.2147/ppa.s367284] [Reference Citation Analysis]
11 Hee Jo E, Eun Moon J, Han Chang M, Jin Lim Y, Hyun Park J, Hee Lee S, Rae Cho Y, Cho AE, Pil Pack S, Kim HW, Crowley L, Le B, Nukhet AB, Chen Y, Zhong Y, Zhao J, Li Y, Cha H, Hoon Pan J, Kyeom Kim J, Hyup Lee J. Sensitization of GSH synthesis by curcumin curtails acrolein-induced alveolar epithelial apoptosis via Keap1 cysteine conjugation: A randomized controlled trial and experimental animal model of pneumonitis. J Adv Res 2022:S2090-1232(22)00152-7. [PMID: 35772713 DOI: 10.1016/j.jare.2022.06.013] [Reference Citation Analysis]
12 Isa N, Mudhafar D, Ju C, Man KKC, Lau WCY, Cheng LY, Wei L. Effects of Phosphodiesterase-5 Inhibitors in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. COPD 2022;19:300-8. [PMID: 35723554 DOI: 10.1080/15412555.2022.2067525] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Li Y, Zhang P, An Z, Yue C, Wang Y, Liu Y, Yuan X, Ma Y, Li K, Yin Z, Wang L, Wang H. Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations. Respirology 2022. [PMID: 35705329 DOI: 10.1111/resp.14309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Alter P, Orszag J, Wouters EF, Vogelmeier CF, Jörres RA. Differences in the Measurement of Functional Residual Capacity Between Body Plethysmographs of Two Manufacturers. COPD 2022;Volume 17:1477-82. [DOI: 10.2147/copd.s363493] [Reference Citation Analysis]
15 Herth FJF, Kontogianni K, Brock J. Endoscopic Options for Moderate COPD, Chronic Bronchitis, and Uncontrolled Asthma. Semin Respir Crit Care Med 2022. [PMID: 35649430 DOI: 10.1055/s-0042-1747939] [Reference Citation Analysis]
16 Li J, Baker J, Higham A, Shah R, Montero-Fernandez A, Murray C, Cooper N, Lucas C, Fox C, Singh D, Lea S. COPD lung studies of Nrf2 expression and the effects of Nrf2 activators. Inflammopharmacology 2022. [PMID: 35441963 DOI: 10.1007/s10787-022-00967-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Suissa S, Dell'Aniello S, Ernst P. Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice. COPD 2022;19:133-41. [PMID: 35392746 DOI: 10.1080/15412555.2022.2045265] [Reference Citation Analysis]
18 Suissa S, Dell'Aniello S, Ernst P. Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety. COPD 2022;19:109-17. [PMID: 35385359 DOI: 10.1080/15412555.2022.2035705] [Reference Citation Analysis]
19 Kim J, Choi HG, Kwon MJ, Kim JH, Park J, Hwang YI, Jang SH, Jung K. The Influence of Prior Statin Use on the Prevalence and Exacerbation of Chronic Obstructive Pulmonary Disease in an Adult Population. Front Med 2022;9:842948. [DOI: 10.3389/fmed.2022.842948] [Reference Citation Analysis]
20 Bruni A, Garofalo E, Procopio D, Corrado S, Caroleo A, Biamonte E, Pelaia C, Longhini F. Current Practice of High Flow through Nasal Cannula in Exacerbated COPD Patients. Healthcare 2022;10:536. [DOI: 10.3390/healthcare10030536] [Reference Citation Analysis]
21 Zhu D, Qiao C, Dai H, Hu Y, Xi Q. Diagnostic efficacy of visual subtypes and low attenuation area based on HRCT in the diagnosis of COPD. BMC Pulm Med 2022;22. [DOI: 10.1186/s12890-022-01875-6] [Reference Citation Analysis]
22 Wang H, Yang T, Yu X, Chen Z, Ran Y, Wang J, Dai G, Deng H, Li X, Zhu T. Risk Factors for Length of Hospital Stay in Acute Exacerbation Chronic Obstructive Pulmonary Disease: A Multicenter Cross-Sectional Study. IJGM 2022;Volume 15:3447-58. [DOI: 10.2147/ijgm.s354748] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Koopman M, Franssen FM, Gaffron S, Watz H, Troosters T, Garcia-aymerich J, Paggiaro P, Molins E, Moya M, van Burk L, Maier D, Garcia Gil E, Wouters EF, Vanfleteren LE, Spruit MA. Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study. COPD 2022;Volume 17:517-33. [DOI: 10.2147/copd.s308600] [Reference Citation Analysis]
24 Park SW, Lim M, Kim WJ, Bak SH. Quantitative assessment the longitudinal changes of pulmonary vascular counts in chronic obstructive pulmonary disease. Respir Res 2022;23. [DOI: 10.1186/s12931-022-01953-7] [Reference Citation Analysis]
25 Lam TYW, Nguyen N, Peh HY, Shanmugasundaram M, Chandna R, Tee JH, Ong CB, Hossain MZ, Venugopal S, Zhang T, Xu S, Qiu T, Kong WT, Chakarov S, Srivastava S, Liao W, Kim JS, Teh M, Ginhoux F, Fred Wong WS, Ge R. ISM1 protects lung homeostasis via cell-surface GRP78-mediated alveolar macrophage apoptosis. Proc Natl Acad Sci U S A 2022;119:e2019161119. [PMID: 35046017 DOI: 10.1073/pnas.2019161119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
26 Tanabe N, Kaji S, Shima H, Shiraishi Y, Maetani T, Oguma T, Sato S, Hirai T. Kernel Conversion for Robust Quantitative Measurements of Archived Chest Computed Tomography Using Deep Learning-Based Image-to-Image Translation. Front Artif Intell 2022;4:769557. [DOI: 10.3389/frai.2021.769557] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Frerichs I, Lasarow L, Strodthoff C, Vogt B, Zhao Z, Weiler N. Spatial Ventilation Inhomogeneity Determined by Electrical Impedance Tomography in Patients With Chronic Obstructive Lung Disease. Front Physiol 2021;12:762791. [PMID: 34966289 DOI: 10.3389/fphys.2021.762791] [Reference Citation Analysis]
28 Bishop JA, Spencer LM, Dwyer TJ, McKeough ZJ, McAnulty A, Alison JA. Changes in Exercise Capacity and Health-Related Quality of Life at Four and Eight Weeks of a Pulmonary Rehabilitation Program in People with COPD. COPD 2021;:1-9. [PMID: 34927525 DOI: 10.1080/15412555.2021.2013793] [Reference Citation Analysis]
29 Haukeland-Parker S, Frisk B, Spruit MA, Stafne SN, Johannessen HH. Treatment of urinary incontinence in women with chronic obstructive pulmonary disease-a randomised controlled study. Trials 2021;22:900. [PMID: 34895285 DOI: 10.1186/s13063-021-05816-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Jovičić Burić D, Erceg M, Antoljak N. Gender differences in specific trends of COPD mortality in Croatia. Public Health 2021;202:26-31. [PMID: 34879319 DOI: 10.1016/j.puhe.2021.10.016] [Reference Citation Analysis]
31 Kahnert K, Jörres RA, Lucke T, Trudzinski FC, Mertsch P, Bickert C, Ficker JH, Behr J, Bals R, Watz H, Welte T, Vogelmeier CF, Alter P; COSYCONET Study Group. Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET. Int J Chron Obstruct Pulmon Dis 2021;16:3189-99. [PMID: 34853511 DOI: 10.2147/COPD.S335029] [Reference Citation Analysis]
32 Gagné M, Hamel C, Lauzier S, Penney SE, Bourbeau J, Moisan J, Boulet LP. Comparative educational outcomes of an active versus passive learning continuing professional development activity on self-management support for respiratory educators: A non-randomized controlled mixed-methods study. Nurse Educ Pract 2021;57:103256. [PMID: 34814074 DOI: 10.1016/j.nepr.2021.103256] [Reference Citation Analysis]
33 Cao X, Gao X, Yu N, Shi M, Wei X, Huang X, Xu S, Pu J, Jin C, Guo Y. Potential Value of Expiratory CT in Quantitative Assessment of Pulmonary Vessels in COPD. Front Med (Lausanne) 2021;8:761804. [PMID: 34722596 DOI: 10.3389/fmed.2021.761804] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Gao P, Tang F, Liu W, He K, Mo Y. Effect of liuzijue qigong on patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27344. [PMID: 34731105 DOI: 10.1097/MD.0000000000027344] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
35 Vianello A, Guarnieri G, Braccioni F, Molena B, Lococo S, Achille A, Lionello F, Salviati L, Caminati M, Senna G. Correlation between α1-Antitrypsin Deficiency and SARS-CoV-2 Infection: Epidemiological Data and Pathogenetic Hypotheses. J Clin Med 2021;10:4493. [PMID: 34640510 DOI: 10.3390/jcm10194493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Abudureheman Z, Li L, Zhong X, Xu J, Gong H, Yilamujiang S, Ren J, Xie C, Zheng A, Tuerxun D, Abudukadeer A, Aini P, Xu A, Zou X. The rs74794265 SNP of the SREK1 Gene is Associated with COPD in Kashi, China. Int J Chron Obstruct Pulmon Dis 2021;16:2631-6. [PMID: 34556983 DOI: 10.2147/COPD.S321150] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Higuchi S, Kohno T, Kohsaka S, Shiraishi Y, Takei M, Goda A, Shoji S, Nagatomo Y, Yoshikawa T. Different Impact of Beta-Blockers on Long-Term Mortality in Heart Failure Patients with and without Chronic Obstructive Pulmonary Disease. J Clin Med 2021;10:4378. [PMID: 34640396 DOI: 10.3390/jcm10194378] [Reference Citation Analysis]
38 Sansbury LB, Rothnie KJ, Bains C, Compton C, Anley G, Ismaila AS. Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England. Int J Chron Obstruct Pulmon Dis 2021;16:2591-604. [PMID: 34552325 DOI: 10.2147/COPD.S318969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
39 Suissa S, Dell'Aniello S, Ernst P. Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality. COPD 2021;:1-9. [PMID: 34544314 DOI: 10.1080/15412555.2021.1977789] [Reference Citation Analysis]
40 Fazleen A, Wilkinson T. Early COPD: current evidence for diagnosis and management. Ther Adv Respir Dis 2020;14:1753466620942128. [PMID: 32664818 DOI: 10.1177/1753466620942128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
41 Wu YK, Su WL, Yang MC, Chen SY, Wu CW, Lan CC. Characterization Associated with the Frequent Severe Exacerbator Phenotype in COPD Patients. Int J Chron Obstruct Pulmon Dis 2021;16:2475-85. [PMID: 34511892 DOI: 10.2147/COPD.S317177] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
42 Kahnert K, Lutter JI, Welte T, Alter P, Behr J, Herth F, Kauczor HU, Söhler S, Pfeifer M, Watz H, Vogelmeier CF, Bals R, Jörres RA, Trudzinski FC. Impact of the COVID-19 pandemic on the behaviour and health status of patients with COPD: results from the German COPD cohort COSYCONET. ERJ Open Res 2021;7:00242-2021. [PMID: 34430659 DOI: 10.1183/23120541.00242-2021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Alameda C, Matía ÁC, Casado V. Predictors for mortality due to acute exacerbation of COPD in primary care: Derivation of a clinical prediction rule in a multicentre cohort study. Eur J Gen Pract 2021;27:211-20. [PMID: 34355618 DOI: 10.1080/13814788.2021.1959547] [Reference Citation Analysis]
44 Seixas S, Kolbe AR, Gomes S, Sucena M, Sousa C, Vaz Rodrigues L, Teixeira G, Pinto P, Tavares de Abreu T, Bárbara C, Semedo J, Mota L, Carvalho AS, Matthiesen R, Marques PI, Pérez-Losada M. Comparative analysis of the bronchoalveolar microbiome in Portuguese patients with different chronic lung disorders. Sci Rep 2021;11:15042. [PMID: 34294826 DOI: 10.1038/s41598-021-94468-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Raphaely RA, Mongiardo MA, Goldstein RL, Robinson SA, Wan ES, Moy ML. Pain in Veterans with COPD: relationship with physical activity and exercise capacity. BMC Pulm Med 2021;21:238. [PMID: 34266401 DOI: 10.1186/s12890-021-01601-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Geidl W, Carl J, Schuler M, Mino E, Lehbert N, Wittmann M, Pfeifer K, Schultz K. Long-Term Benefits of Adding a Pedometer to Pulmonary Rehabilitation for COPD: The Randomized Controlled STAR Trial. Int J Chron Obstruct Pulmon Dis 2021;16:1977-88. [PMID: 34239299 DOI: 10.2147/COPD.S304976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Adi O, Via G, Salleh SH, Chuan TW, Rahman JA, Muhammad NAN, Atan R, Yunos N. Randomized clinical trial comparing helmet continuous positive airway pressure (hCPAP) to facemask continuous positive airway pressure (fCPAP) for the treatment of acute respiratory failure in the emergency department. Am J Emerg Med 2021;49:385-92. [PMID: 34271286 DOI: 10.1016/j.ajem.2021.06.031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Zhao Y, Li M, Yang Y, Wu T, Huang Q, Wu Q, Ren C. Identification of Macrophage Polarization-Related Genes as Biomarkers of Chronic Obstructive Pulmonary Disease Based on Bioinformatics Analyses. Biomed Res Int 2021;2021:9921012. [PMID: 34250093 DOI: 10.1155/2021/9921012] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
49 Jiang M, Cai R, Wang J, Li Z, Xu D, Jing J, Zhang F, Li F, Ding J. ILC2 Cells Promote Th2 Cell Differentiation in AECOPD Through Activated Notch-GATA3 Signaling Pathway. Front Immunol 2021;12:685400. [PMID: 34354706 DOI: 10.3389/fimmu.2021.685400] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
50 Tanabe N, Kaji S, Sato S, Yokoyama T, Oguma T, Tanizawa K, Handa T, Sakajo T, Hirai T. A homological approach to a mathematical definition of pulmonary fibrosis and emphysema on computed tomography. J Appl Physiol (1985) 2021;131:601-12. [PMID: 34138650 DOI: 10.1152/japplphysiol.00150.2021] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
51 Kosmidis C, Hashad R, Mathioudakis AG, McCahery T, Richardson MD, Vestbo J. Impact of self-reported environmental mould exposure on COPD outcomes. Pulmonology 2021:S2531-0437(21)00096-9. [PMID: 34130917 DOI: 10.1016/j.pulmoe.2021.05.003] [Reference Citation Analysis]
52 Suissa S. Perplexing mortality data from triple therapy trials in COPD. Lancet Respir Med 2021;9:684-5. [PMID: 34126054 DOI: 10.1016/S2213-2600(21)00238-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
53 Sönnerfors P, Skavberg Roaldsen K, Ståhle A, Wadell K, Halvarsson A. Access to, use, knowledge, and preferences for information technology and technical equipment among people with chronic obstructive pulmonary disease (COPD) in Sweden. A cross-sectional survey study. BMC Med Inform Decis Mak 2021;21:185. [PMID: 34112150 DOI: 10.1186/s12911-021-01544-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Candemir I. The narrative review of chronic obstructive pulmonary disease management in Turkey: medical treatment, pulmonary rehabilitation and endobronchial volume reduction. J Thorac Dis 2021;13:3907-17. [PMID: 34277080 DOI: 10.21037/jtd-20-2271] [Reference Citation Analysis]
55 Xiao T, Wijnant SRA, Licher S, Terzikhan N, Lahousse L, Ikram MK, Brusselle GG, Ikram MA. Lung Function Impairment and the Risk of Incident Dementia: The Rotterdam Study. J Alzheimers Dis 2021;82:621-30. [PMID: 34057085 DOI: 10.3233/JAD-210162] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Kim SH, Ahn HS, Park JS, Yeom J, Yu J, Kim K, Oh YM. A Proteomics-Based Analysis of Blood Biomarkers for the Diagnosis of COPD Acute Exacerbation. Int J Chron Obstruct Pulmon Dis 2021;16:1497-508. [PMID: 34113087 DOI: 10.2147/COPD.S308305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
57 Rê A, Fonseca FR, Queiroz AP, Reis CMD, Bahl MM, Kocks J, Molen TV, Maurici R. Brazilian version of the Clinical COPD Questionnaire, administered by interview: reliability and validity measurement properties. J Bras Pneumol 2021;47:e20200371. [PMID: 34076173 DOI: 10.36416/1806-3756/e20200371] [Reference Citation Analysis]
58 Zhou L, Tao Y, Li H, Niu Y, Li L, Kan H, Xie J, Chen R. Acute effects of fine particulate matter constituents on cardiopulmonary function in a panel of COPD patients. Sci Total Environ 2021;770:144753. [PMID: 33515878 DOI: 10.1016/j.scitotenv.2020.144753] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
59 Strang P, Fürst P, Hedman C, Bergqvist J, Adlitzer H, Schultz T. Chronic obstructive pulmonary disease and lung cancer: access to palliative care, emergency room visits and hospital deaths. BMC Pulm Med 2021;21:170. [PMID: 34011344 DOI: 10.1186/s12890-021-01533-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
60 Amado CA, Muñoz P, García-Unzueta M, Agüero J, Tello S, Fueyo P, Vega C, Lavín BA, Guerra RA, Casanova C. High parathyroid hormone predicts exacerbations in COPD patients with hypovitaminosis D. Respir Med 2021;182:106416. [PMID: 33894440 DOI: 10.1016/j.rmed.2021.106416] [Reference Citation Analysis]
61 Lutter JI, Jörres RA, Trudzinski FC, Alter P, Kellerer C, Watz H, Welte T, Bals R, Kauffmann-Guerrero D, Behr J, Holle R, F Vogelmeier C, Kahnert K; COSYCONET study group. Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort - Determinants and Consequences. Int J Chron Obstruct Pulmon Dis 2021;16:987-98. [PMID: 33883892 DOI: 10.2147/COPD.S304532] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
62 Singh D. Pharmacological treatment of stable chronic obstructive pulmonary disease. Respirology 2021;26:643-51. [PMID: 33829619 DOI: 10.1111/resp.14046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
63 Wang Z, Zuo Y, Gao Z. CircANKRD11 Knockdown Protects HPMECs from Cigarette Smoke Extract-Induced Injury by Regulating miR-145-5p/BRD4 Axis. Int J Chron Obstruct Pulmon Dis 2021;16:887-99. [PMID: 33833509 DOI: 10.2147/COPD.S300332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Zhu Z, Li J, Si J, Ma B, Shi H, Lv J, Cao W, Guo Y, Millwood IY, Walters RG, Lin K, Yang L, Chen Y, Du H, Yu B, Hasegawa K, Camargo CA Jr, Moffatt MF, Cookson WOC, Chen J, Chen Z, Li L, Yu C, Liang L. A large-scale genome-wide association analysis of lung function in the Chinese population identifies novel loci and highlights shared genetic aetiology with obesity. Eur Respir J 2021;58:2100199. [PMID: 33766948 DOI: 10.1183/13993003.00199-2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Tanabe N, Shimizu K, Terada K, Sato S, Suzuki M, Shima H, Oguma A, Oguma T, Konno S, Nishimura M, Hirai T. Central airway and peripheral lung structures in airway disease-dominant COPD. ERJ Open Res 2021;7:00672-2020. [PMID: 33778061 DOI: 10.1183/23120541.00672-2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
66 Spruit MA, Van't Hul A, Vreeken HL, Beekman E, Post MHT, Meerhoff GA, Van der Valk AL, Zagers C, Sillen MJH, Vooijs M, Custers J, Muris J, Langer D, Donkers J, Bregman M, Tissink L, Bergkamp E, Wempe J, Houben-Wilke S, Augustin IML, Bij de Vaate E, Franssen FFM, Van Ranst D, Van der Vaart H, Antons J, Van Doormaal M, Koolen EH, Van der Wees P, Van Snippenburg R, Janssen DJA, Simons S. Profiling of Patients with COPD for Adequate Referral to Exercise-Based Care: The Dutch Model. Sports Med 2020;50:1421-9. [PMID: 32333261 DOI: 10.1007/s40279-020-01286-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
67 Miao TW, Xiao W, Du LY, Mao B, Huang W, Chen XM, Li C, Wang Y, Fu JJ. High expression of SPP1 in patients with chronic obstructive pulmonary disease (COPD) is correlated with increased risk of lung cancer. FEBS Open Bio 2021;11:1237-49. [PMID: 33626243 DOI: 10.1002/2211-5463.13127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
68 Zhang L, Nie X, Luo Z, Wei B, Teng G. The Role of Human Leukocyte Antigen-DR in Regulatory T Cells in Patients with Virus-Induced Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Med Sci Monit 2021;27:e928051. [PMID: 33651771 DOI: 10.12659/MSM.928051] [Reference Citation Analysis]
69 Vafadar Moradi E, Pishbin E, Habibzadeh SR, Talebi Doluee M, Soltanifar A. The Adjunctive Effect of Intravenous Magnesium Sulfate in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Clinical Trial. Acad Emerg Med 2021;28:359-62. [PMID: 32542879 DOI: 10.1111/acem.14050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Orr JE, Azofra AS, Tobias LA. Management of Chronic Respiratory Failure in Chronic Obstructive Pulmonary Disease: High-Intensity and Low-Intensity Ventilation. Sleep Med Clin 2020;15:497-509. [PMID: 33131660 DOI: 10.1016/j.jsmc.2020.08.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Baidoo PK, Odei JB, Ansu V, Segbefia M, Holdbrook-Smith H. Predictors of hip fracture mortality in Ghana: a single-center prospective study. Arch Osteoporos 2021;16:35. [PMID: 33609199 DOI: 10.1007/s11657-021-00883-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Yangui F, Touil A, Antit S, Zakhama L, Charfi MR. COPD prevalence in smokers with stable ischemic heart disease: A cross-sectional study in Tunisia. Respir Med 2021;179:106335. [PMID: 33621707 DOI: 10.1016/j.rmed.2021.106335] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
73 Csoma B, Bikov A, Tóth F, Losonczy G, Müller V, Lázár Z. Blood eosinophils on hospital admission for COPD exacerbation do not predict the recurrence of moderate and severe relapses. ERJ Open Res 2021;7:00543-2020. [PMID: 33585654 DOI: 10.1183/23120541.00543-2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
74 Fischer AM, Yacoub B, Savage RH, Martinez JD, Wichmann JL, Sahbaee P, Grbic S, Varga-Szemes A, Schoepf UJ. Machine Learning/Deep Neuronal Network: Routine Application in Chest Computed Tomography and Workflow Considerations. J Thorac Imaging 2020;35 Suppl 1:S21-7. [PMID: 32317574 DOI: 10.1097/RTI.0000000000000498] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
75 Kooij L, Vos PJE, Dijkstra A, van Harten WH. Effectiveness of a Mobile Health and Self-Management App for High-Risk Patients With Chronic Obstructive Pulmonary Disease in Daily Clinical Practice: Mixed Methods Evaluation Study. JMIR Mhealth Uhealth 2021;9:e21977. [PMID: 33538699 DOI: 10.2196/21977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
76 Fujimoto S, Fujita Y, Kadota T, Araya J, Kuwano K. Intercellular Communication by Vascular Endothelial Cell-Derived Extracellular Vesicles and Their MicroRNAs in Respiratory Diseases. Front Mol Biosci 2020;7:619697. [PMID: 33614707 DOI: 10.3389/fmolb.2020.619697] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
77 Zuberi FF, Bader N, Rasheed T, Zuberi BF. Association between insulin resistance and BMI with FEV1 in non-hypoxemic COPD out-patients. Clin Respir J 2021;15:513-21. [PMID: 33497542 DOI: 10.1111/crj.13336] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Bai J, Zhang Y, Tang C, Hou Y, Ai X, Chen X, Zhang Y, Wang X, Meng X. Gallic acid: Pharmacological activities and molecular mechanisms involved in inflammation-related diseases. Biomedicine & Pharmacotherapy 2021;133:110985. [DOI: 10.1016/j.biopha.2020.110985] [Cited by in Crossref: 13] [Cited by in F6Publishing: 62] [Article Influence: 13.0] [Reference Citation Analysis]
79 Swartzendruber JA, Nicholson BJ, Murthy AK. The Role of Connexin 43 in Lung Disease. Life (Basel) 2020;10:E363. [PMID: 33352732 DOI: 10.3390/life10120363] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
80 Lim JU, Kang HS, Yeo CD, Kim JS, Park CK, Kim YH, Kim JW, Kim SJ, Lee SH. Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study. Int J Chron Obstruct Pulmon Dis 2020;15:3323-34. [PMID: 33363365 DOI: 10.2147/COPD.S274354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Guo Y, Xing Z, Shan G, Janssens JP, Sun T, Chai D, Liu W, Wang Y, Ma Y, Tong Y, Huang Y, Cao Y, Wang C. Prevalence and Risk Factors for COPD at High Altitude: A Large Cross-Sectional Survey of Subjects Living Between 2,100-4,700 m Above Sea Level. Front Med (Lausanne) 2020;7:581763. [PMID: 33344472 DOI: 10.3389/fmed.2020.581763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
82 Yang T, Liu X, Wang Y, Song C, Ma R, Yin Y, Xie J. The effect of Tai Ji and Qigong in patients with chronic obstructive pulmonary disease: A systematic review and meta-analyses. European Journal of Integrative Medicine 2020;40:101223. [DOI: 10.1016/j.eujim.2020.101223] [Reference Citation Analysis]
83 Day K, Ostridge K, Conway J, Cellura D, Watson A, Spalluto CM, Staples KJ, Thompson B, Wilkinson T. Interrelationships Among Small Airways Dysfunction, Neutrophilic Inflammation, and Exacerbation Frequency in COPD. Chest 2021;159:1391-9. [PMID: 33245876 DOI: 10.1016/j.chest.2020.11.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
84 Tanabe N, Rhee CK, Sato S, Muro S, Shima H, Tanimura K, Jung KS, Yoo KH, Hirai T. Disproportionally Impaired Diffusion Capacity Relative to Airflow Limitation in COPD. COPD 2020;17:627-34. [PMID: 33222554 DOI: 10.1080/15412555.2020.1845639] [Reference Citation Analysis]
85 Liu Y, Zeng S, Li Y, Zhuang G, Su Y, Liu X, Chen L, Feng Q. The effect of acupoint application of traditional Chinese medicine for the treatment of chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e22730. [PMID: 33120771 DOI: 10.1097/MD.0000000000022730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
86 Scarlata S, Finamore P, Meszaros M, Dragonieri S, Bikov A. The Role of Electronic Noses in Phenotyping Patients with Chronic Obstructive Pulmonary Disease. Biosensors (Basel) 2020;10:E171. [PMID: 33187142 DOI: 10.3390/bios10110171] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
87 Valipour A, Fernandez-Bussy S, Ing AJ, Steinfort DP, Snell GI, Williamson JP, Saghaie T, Irving LB, Dabscheck EJ, Krimsky WS, Waldstreicher J. Bronchial Rheoplasty for Treatment of Chronic Bronchitis. Twelve-Month Results from a Multicenter Clinical Trial. Am J Respir Crit Care Med 2020;202:681-9. [PMID: 32407638 DOI: 10.1164/rccm.201908-1546OC] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
88 Higham A, Mathioudakis A, Vestbo J, Singh D. COVID-19 and COPD: a narrative review of the basic science and clinical outcomes. Eur Respir Rev 2020;29:200199. [PMID: 33153991 DOI: 10.1183/16000617.0199-2020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
89 Tanabe N, Sato S, Oguma T, Shima H, Kubo T, Kozawa S, Koizumi K, Sato A, Togashi K, Matsumoto H, Hirai T. Influence of Asthma Onset on Airway Dimensions on Ultra-high-resolution Computed Tomography in Chronic Obstructive Pulmonary Disease. J Thorac Imaging 2021;36:224-30. [PMID: 33156159 DOI: 10.1097/RTI.0000000000000568] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
90 Shi H, Xu J, Feng Q, Sun J, Yang Y, Zhao J, Zhou X, Niu H, He P, Liu J, Li Q, Ding Y. The effect of CYP3A4 genetic variants on the susceptibility to chronic obstructive pulmonary disease in the Hainan Han population. Genomics 2020;112:4399-405. [DOI: 10.1016/j.ygeno.2020.07.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Li J, Jiang J, Jing C, Zheng W, Pan H. Efficacy and safety of Sangbaipi Decoction in patients with acute exacerbation of chronic obstructive pulmonary disease: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2020;99:e22917. [PMID: 33126351 DOI: 10.1097/MD.0000000000022917] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Bourbeau J, Gagnon S, Ross B. Pulmonary Rehabilitation. Clin Chest Med 2020;41:513-28. [PMID: 32800203 DOI: 10.1016/j.ccm.2020.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
93 Deng L, Zhang X, Dong Y, Wang L, Chen K, Zheng M, Yang Z, Tang H, Liao W, Shi Q. Erchen decoction combined with Sanziyangqin decoction for chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e22315. [PMID: 33019407 DOI: 10.1097/MD.0000000000022315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Alam M, Shehzad MI, Hussain S, Paras I, Kanwal M, Mushtaq A. Spirometry Assessment and Correlation With Postoperative Pulmonary Complications in Cardiac Surgery Patients. Cureus 2020;12:e11105. [PMID: 33240701 DOI: 10.7759/cureus.11105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Beyer C, Pizzini A, Boehm A, Loeffler-Ragg J, Weiss G, Feuchtner G, Bauer A, Friedrich G, Plank F. Current symptom-based risk scores for stable coronary artery disease evaluation are not applicable in COPD patients. ERJ Open Res 2020;6:00492-2020. [PMID: 33123555 DOI: 10.1183/23120541.00492-2020] [Reference Citation Analysis]
96 Jiang JJ, Chen SM, Li HY, Xie QM, Yang YM. TLR3 inhibitor and tyrosine kinase inhibitor attenuate cigarette smoke/poly I:C-induced airway inflammation and remodeling by the EGFR/TLR3/MAPK signaling pathway. Eur J Pharmacol 2021;890:173654. [PMID: 33068589 DOI: 10.1016/j.ejphar.2020.173654] [Reference Citation Analysis]
97 Vestbo J, Janson C, Nuevo J, Price D. Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design. ERJ Open Res 2020;6:00044-2020. [PMID: 33083435 DOI: 10.1183/23120541.00044-2020] [Reference Citation Analysis]
98 Mahalanobish S, Dutta S, Saha S, Sil PC. Melatonin induced suppression of ER stress and mitochondrial dysfunction inhibited NLRP3 inflammasome activation in COPD mice. Food and Chemical Toxicology 2020;144:111588. [DOI: 10.1016/j.fct.2020.111588] [Cited by in Crossref: 12] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
99 Lhote R, Chilles M, Groh M, Puéchal X, Guilpain P, Ackermann F, Amoura Z, Annesi-Maesano I, Barba T, Catherinot E, Cohen-Aubart F, Cohen P, Cottin V, Couderc LJ, De Boysson H, Delbrel X, Dominique S, Duhaut P, Fain O, Hachulla E, Hamidou M, Kahn JE, Legendre C, Le Quellec A, Lhote F, Lifermann F, Mathian A, Néel A, Nunes H, Subra JF, Terrier B, Mouthon L, Diot E, Guillevin L, Brillet PY, Tcherakian C; French Vasculitis Study Group (FVSG) and the Groupe d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires (GERM“O”P). Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody-associated Vasculitis-related Bronchiectasis: Data from 61 Patients. J Rheumatol 2020;47:1522-31. [PMID: 31787599 DOI: 10.3899/jrheum.190313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
100 Iyer AS, Dionne-Odom JN, Ford SM, Crump Tims SL, Sockwell ED, Ivankova NV, Brown CJ, Tucker RO, Dransfield MT, Bakitas MA. A Formative Evaluation of Patient and Family Caregiver Perspectives on Early Palliative Care in Chronic Obstructive Pulmonary Disease across Disease Severity. Ann Am Thorac Soc 2019;16:1024-33. [PMID: 31039003 DOI: 10.1513/AnnalsATS.201902-112OC] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
101 Bishop J, Spencer L, Alison J. Effect of a pulmonary rehabilitation programme of 8 weeks compared to 12 weeks duration on exercise capacity in people with chronic obstructive pulmonary disease (PuRe Duration): protocol for a randomised controlled trial. BMJ Open Respir Res 2020;7:e000687. [PMID: 32933927 DOI: 10.1136/bmjresp-2020-000687] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Mathioudakis AG, Abroug F, Agusti A, Bakke P, Bartziokas K, Beghe B, Bikov A, Bradbury T, Brusselle G, Cadus C, Coleman C, Contoli M, Corlateanu A, Corlateanu O, Criner G, Csoma B, Emelyanov A, Faner R, Romero GF, Hammouda Z, Horváth P, Huerta AG, Jacobs M, Jenkins C, Joos G, Kharevich O, Kostikas K, Lapteva E, Lazar Z, Leuppi JD, Liddle C, López-Giraldo A, McDonald VM, Nielsen R, Papi A, Saraiva I, Sergeeva G, Sioutkou A, Sivapalan P, Stovold E, Wang H, Wen F, Yorke J, Williamson PR, Vestbo J, Jensen JU. Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol. ERJ Open Res 2020;6:00193-2020. [PMID: 32964006 DOI: 10.1183/23120541.00193-2020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
103 Dorner TE, Brath H, Kautzky-Willer A. Sex-specific trends in smoking prevalence over seven years in different Austrian populations: results of a time-series cross-sectional analysis. BMJ Open 2020;10:e035235. [PMID: 32907892 DOI: 10.1136/bmjopen-2019-035235] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
104 Tanabe N, Sato S, Muro S, Shima H, Oguma T, Tanimura K, Sato A, Hirai T. Regional lung deflation with increased airway volume underlies the functional response to bronchodilators in chronic obstructive pulmonary disease. Physiol Rep 2019;7:e14330. [PMID: 31880096 DOI: 10.14814/phy2.14330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
105 Sönnerfors P, Wadell K, Dohrn IM, Nyberg A, Runold M, Halvarsson A. Use of an eHealth tool for exercise training and online contact in people with severe chronic obstructive pulmonary disease on long-term oxygen treatment: A feasibility study. Health Informatics J 2020;26:3184-200. [PMID: 32880209 DOI: 10.1177/1460458220945429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
106 Kahnert K, Jörres RA, Kauczor HU, Biederer J, Jobst B, Alter P, Biertz F, Mertsch P, Lucke T, Lutter JI, Trudzinski FC, Behr J, Bals R, Watz H, Vogelmeier CF, Welte T; COSYCONET Study-Group., Names of participating study nurses. Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET. Respir Med 2020;172:106117. [PMID: 32891937 DOI: 10.1016/j.rmed.2020.106117] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Saeed MI, Sivapalan P, Eklöf J, Ulrik CS, Pisinger C, Lapperre T, Tønnesen P, Hoyer N, Janner J, Karlsson ML, Bech CS, Marså K, Godtfredsen N, Brøndum E, Munk B, Raaschou M, Browatzski A, Lütken P, Jensen JS. TOB-STOP-COP (TOBacco STOP in COPd trial): study protocol-a randomized open-label, superiority, multicenter, two-arm intervention study of the effect of "high-intensity" vs. "low-intensity" smoking cessation intervention in active smokers with chronic obstructive pulmonary disease. Trials 2020;21:730. [PMID: 32825845 DOI: 10.1186/s13063-020-04653-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
108 Schreiber J, Sonnenburg T, Luecke E. Inhaler devices in asthma and COPD patients - a prospective cross-sectional study on inhaler preferences and error rates. BMC Pulm Med 2020;20:222. [PMID: 32819337 DOI: 10.1186/s12890-020-01246-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
109 Sprooten RTM, Rohde GGU, Janssen MTHF, Cobben NAM, Wouters EFM, Franssen FME. Predictors for long-term mortality in COPD patients requiring non-invasive positive pressure ventilation for the treatment of acute respiratory failure. Clin Respir J 2020;14:1144-52. [PMID: 32780940 DOI: 10.1111/crj.13251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
110 Westerdahl E, Osadnik C, Emtner M. Airway clearance techniques for patients with acute exacerbations of chronic obstructive pulmonary disease: Physical therapy practice in Sweden. Chron Respir Dis 2019;16:1479973119855868. [PMID: 31220934 DOI: 10.1177/1479973119855868] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
111 Koch R, Augusto TRL, Ramos AG, Müller PT. Inspiratory Muscle Training Potentiates the Beneficial Effects of Proportional Assisted Ventilation on Exertional Dyspnea and Exercise Tolerance in COPD: A Proof-of-Concept Randomized and Controlled Trial. COPD 2020;17:384-91. [PMID: 32689839 DOI: 10.1080/15412555.2020.1789085] [Reference Citation Analysis]
112 Lv Z, Hu P, Jiang Y, Yang W, Wang R, Wang K, Fan X. Changes in Spatial Working Memory in Stable Chronic Obstructive Pulmonary Disease: A Retrospective Study. Biomed Res Int 2020;2020:7363712. [PMID: 32775438 DOI: 10.1155/2020/7363712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
113 Higham A, Scott T, Li J, Gaskell R, Dikwa AB, Shah R, Montero-Fernandez MA, Lea S, Singh D. Effects of corticosteroids on COPD lung macrophage phenotype and function. Clin Sci (Lond) 2020;134:751-63. [PMID: 32227160 DOI: 10.1042/CS20191202] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
114 Horne BD, Hegewald MJ, Crim C, Rea S, Bair TL, Blagev DP. The Summit Score Stratifies Mortality and Morbidity in Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2020;15:1741-50. [PMID: 32764918 DOI: 10.2147/COPD.S254437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
115 Mathioudakis AG, Sivapalan P, Papi A, Vestbo J; DECODE-NET (DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork) Investigators. The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork (DECODE-NET): rationale and vision. Eur Respir J 2020;56:2000627. [PMID: 32616552 DOI: 10.1183/13993003.00627-2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
116 Lázár Z, Horváth A, Tomisa G, Tamási L, Müller V. Impact of Clinical Factors on Generic and Disease-Specific Quality of Life in COPD and Asthma-COPD Overlap with Exacerbations. Pulm Med 2020;2020:6164343. [PMID: 32789027 DOI: 10.1155/2020/6164343] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
117 Chalmers JD, Laska IF, Franssen FME, Janssens W, Pavord I, Rigau D, McDonnell MJ, Roche N, Sin DD, Stolz D, Suissa S, Wedzicha J, Miravitlles M. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J 2020;55:2000351. [PMID: 32366483 DOI: 10.1183/13993003.00351-2020] [Cited by in Crossref: 35] [Cited by in F6Publishing: 52] [Article Influence: 17.5] [Reference Citation Analysis]
118 Kostikas K, Rhee CK, Hurst JR, Agostoni P, Cao H, Fogel R, Jones R, Kocks JWH, Mezzi K, Wan Yau Ming S, Ryan R, Price DB. Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study. Pragmat Obs Res 2020;11:55-66. [PMID: 32581622 DOI: 10.2147/POR.S250451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
119 Lutter JI, Jörres RA, Kahnert K, Schwarzkopf L, Studnicka M, Karrasch S, Schulz H, Vogelmeier CF, Holle R; COSYCONET Study Group. Health-related quality of life associates with change in FEV1 in COPD: results from the COSYCONET cohort. BMC Pulm Med 2020;20:148. [PMID: 32471493 DOI: 10.1186/s12890-020-1147-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
120 Dentali F, Pomero F, Micco PD, La Regina M, Landini F, Mumoli N, Pieralli F, Giorgi-Pierfranceschi M, Re R, Vitale J, Fabbri LM, Fontanella A, Arioli D; Young-FADOI Study Group. Prevalence and risk factors for pulmonary embolism in patients with suspected acute exacerbation of COPD: a multi-center study. Eur J Intern Med 2020;80:54-9. [PMID: 32474052 DOI: 10.1016/j.ejim.2020.05.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
121 Mathioudakis AG, Bikov A, Foden P, Lahousse L, Brusselle G, Singh D, Vestbo J. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. Eur Respir J 2020;55:1902119. [PMID: 32108044 DOI: 10.1183/13993003.02119-2019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
122 Bikov A, Lange P, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Dixon IJ, Martinez FJ, Newby DE, Yates JC, Vestbo J. FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. Int J Chron Obstruct Pulmon Dis 2020;15:1135-42. [PMID: 32547001 DOI: 10.2147/COPD.S242809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
123 Holmner Å, Öhberg F, Wiklund U, Bergmann E, Blomberg A, Wadell K. How stable is lung function in patients with stable chronic obstructive pulmonary disease when monitored using a telehealth system? A longitudinal and home-based study. BMC Med Inform Decis Mak 2020;20:87. [PMID: 32398161 DOI: 10.1186/s12911-020-1103-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
124 Gong S, Pu Y, Xie L, Yang X, Mao H. Fraction of Exhaled Nitric Oxide Is Elevated in Patients With Stable Chronic Obstructive Pulmonary Disease: A Meta-analysis. Am J Med Sci 2020;360:166-75. [PMID: 32536416 DOI: 10.1016/j.amjms.2020.04.038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Zinellu A, Zinellu E, Sotgiu E, Fois AG, Paliogiannis P, Scano V, Piras B, Sotgia S, Mangoni AA, Carru C, Pirina P. Systemic transsulfuration pathway thiol concentrations in chronic obstructive pulmonary disease patients. Eur J Clin Invest 2020;:e13267. [PMID: 32378181 DOI: 10.1111/eci.13267] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
126 Bruni A, Garofalo E, Cammarota G, Murabito P, Astuto M, Navalesi P, Luzza F, Abenavoli L, Longhini F. High Flow Through Nasal Cannula in Stable and Exacerbated Chronic Obstructive Pulmonary Disease Patients. Rev Recent Clin Trials 2019;14:247-60. [PMID: 31291880 DOI: 10.2174/1574887114666190710180540] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
127 Singh D. Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects. Tuberc Respir Dis (Seoul) 2020;83:185-94. [PMID: 32578413 DOI: 10.4046/trd.2020.0026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
128 Hou J, Sun Y. Role of Regulatory T Cells in Disturbed Immune Homeostasis in Patients With Chronic Obstructive Pulmonary Disease. Front Immunol 2020;11:723. [PMID: 32411140 DOI: 10.3389/fimmu.2020.00723] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
129 Dicker AJ, Huang JTJ, Lonergan M, Keir HR, Fong CJ, Tan B, Cassidy AJ, Finch S, Mullerova H, Miller BE, Tal-Singer R, Chalmers JD. The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2021;147:158-67. [PMID: 32353489 DOI: 10.1016/j.jaci.2020.02.040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
130 Chis AF, Pop CM. Correlations between neutrophil to lymphocyte ratio, blood eosinophils and clinical characteristics in chronic obstructive pulmonary disease. Med Pharm Rep 2020;93:169-74. [PMID: 32478323 DOI: 10.15386/mpr-1412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Holm AM, Andreassen SL, Christensen VL, Kongerud J, Almås Ø, Auråen H, Henriksen AH, Aaberge IS, Klingenberg O, Rustøen T. Hypogammaglobulinemia and Risk of Exacerbation and Mortality in Patients with COPD. Int J Chron Obstruct Pulmon Dis 2020;15:799-807. [PMID: 32368026 DOI: 10.2147/COPD.S236656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Teerapuncharoen K, Wells JM, Raju SV, Raraigh KS, Atalar Aksit M, Cutting GR, Rasmussen L, Nath PH, Bhatt SP, Solomon GM, Dransfield MT, Rowe SM. Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction and Radiographic Bronchiectasis in Current and Former Smokers: A Cross-Sectional Study. Ann Am Thorac Soc 2019;16:150-3. [PMID: 30230364 DOI: 10.1513/AnnalsATS.201805-325RL] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
133 Keller T, Spece LJ, Donovan LM, Udris E, Coggeshall SS, Griffith M, Bryant AD, Casaburi R, Cooper JA Jr, Criner GJ, Diaz PT, Fuhlbrigge AL, Gay SE, Kanner RE, Martinez FJ, Panos RJ, Shade D, Sternberg A, Stibolt T, Stoller JK, Tonascia J, Wise R, Yusen RD, Au DH, Feemster LC. Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life: A Secondary Analysis of the Long-Term Oxygen Treatment Trial. Chest 2020;158:529-38. [PMID: 32278779 DOI: 10.1016/j.chest.2020.02.073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Kefala AM, Fortescue R, Alimani GS, Kanavidis P, McDonnell MJ, Magiorkinis E, Megremis S, Paraskevis D, Voyiatzaki C, Mathioudakis GA, Papageorgiou E, Papadopoulos NG, Vestbo J, Beloukas A, Mathioudakis AG. Prevalence and clinical implications of respiratory viruses in stable chronic obstructive pulmonary disease (COPD) and exacerbations: a systematic review and meta-analysis protocol. BMJ Open 2020;10:e035640. [PMID: 32269027 DOI: 10.1136/bmjopen-2019-035640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
135 Recio Iglesias J, López García F, Almagro P, Varela Aguilar JM, Boixeda Viu R. Spanish clinical practice consensus in internal medicine on chronic obstructive pulmonary disease patients with comorbidities (miEPOC). Curr Med Res Opin 2020;36:1033-42. [PMID: 32228115 DOI: 10.1080/03007995.2020.1749995] [Reference Citation Analysis]
136 Mathioudakis AG, Janssens W, Sivapalan P, Singanayagam A, Dransfield MT, Jensen JS, Vestbo J. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax 2020;75:520-7. [PMID: 32217784 DOI: 10.1136/thoraxjnl-2019-214484] [Cited by in Crossref: 26] [Cited by in F6Publishing: 48] [Article Influence: 13.0] [Reference Citation Analysis]
137 Posthuma R, Vanfleteren LEGW. The STELVIO trial, a game changer for bronchoscopic lung volume reduction in patients with severe emphysema. Breathe (Sheff) 2020;16:200004. [PMID: 32194773 DOI: 10.1183/20734735.0004-2020] [Reference Citation Analysis]
138 Greulich T, Altraja A, Barrecheguren M, Bals R, Chlumsky J, Chorostowska-Wynimko J, Clarenbach C, Corda L, Corsico AG, Ferrarotti I, Esquinas C, Gouder C, Hećimović A, Ilic A, Ivanov Y, Janciauskiene S, Janssens W, Kohler M, Krams A, Lara B, Mahadeva R, McElvaney G, Mornex JF, O'Hara K, Parr D, Piitulainen E, Schmid-Scherzer K, Seersholm N, Stockley RA, Stolk J, Sucena M, Tanash H, Turner A, Ulmeanu R, Wilkens M, Yorgancioğlu A, Zaharie A, Miravitlles M. Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency. ERJ Open Res 2020;6:00181-2019. [PMID: 32154291 DOI: 10.1183/23120541.00181-2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
139 Ruzsa Z, Januszek R, Óriás V, Chyrchel M, Wojtasik-Bakalarz J, Bartuś J, Arif S, Kleczyński P, Tokarek T, Nyerges A, Stanek A, Dudek D, Bartuś S. Mortality and chronic obstructive pulmonary disease in patients treated with endovascular revascularization of the infra-inguinal lower limb arteries from retrograde access. Ann Transl Med 2020;8:206. [PMID: 32309353 DOI: 10.21037/atm.2020.01.57] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
140 Bastos AC, Magalhães GS, Gregório JF, Matos NA, Motta-santos D, Bezerra FS, Santos RAS, Campagnole Santos MJ, Rodrigues-machado MG. Oral formulation angiotensin-(1-7) therapy attenuates pulmonary and systemic damage in mice with emphysema induced by elastase. Immunobiology 2020;225:151893. [DOI: 10.1016/j.imbio.2019.12.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
141 Singh D, Long G, Cançado JE, Higham A. Small airway disease in chronic obstructive pulmonary disease: insights and implications for the clinician. Current Opinion in Pulmonary Medicine 2020;26:162-8. [DOI: 10.1097/mcp.0000000000000637] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
142 Lahousse L, Bahmer T, Cuevas-Ocaña S, Flajolet P, Mathioudakis AG, McDonnell M, Uller L, Schleich F, Dortas Junior S, Idzko M, Singh D, Ricciardolo FLM, Adcock IM, Usmani O, Spanevello A, Bonvini SJ. ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly. ERJ Open Res 2020;6:00341-2019. [PMID: 32083111 DOI: 10.1183/23120541.00341-2019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
143 Xu W, Wang J, He X, Wang J, Wu D, Li G. Bronchoscopic lung volume reduction procedures for emphysema: A network meta-analysis. Medicine (Baltimore) 2020;99:e18936. [PMID: 32000409 DOI: 10.1097/MD.0000000000018936] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
144 Camacho OM, Hedge A, Lowe F, Newland N, Gale N, McEwan M, Proctor C. Statistical analysis plan for "A randomised, controlled study to evaluate the effects of switching from cigarette smoking to using a tobacco heating product on health effect indicators in healthy subjects". Contemp Clin Trials Commun 2020;17:100535. [PMID: 32072070 DOI: 10.1016/j.conctc.2020.100535] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
145 Deshpande C, Alaparthi GK, Krishnan S, Chakravarthy Bairapareddy K, Ramakrishna A, Acharya V. Comparison of Londrina activities of daily living protocol and Glittre ADL test on cardio-pulmonary response in patients with COPD: a cross-sectional study. Multidiscip Respir Med 2020;15:694. [PMID: 33324483 DOI: 10.4081/mrm.2020.694] [Reference Citation Analysis]
146 Harlander M, Lestan D, Turel M. Chitotriosidase Activity in Plasma and COPD Exacerbations. Lung 2020;198:299-306. [PMID: 31982942 DOI: 10.1007/s00408-020-00331-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
147 Wouters EF, Posthuma R, Koopman M, Liu WY, Sillen MJ, Hajian B, Sastry M, Spruit MA, Franssen FM. An update on pulmonary rehabilitation techniques for patients with chronic obstructive pulmonary disease. Expert Rev Respir Med 2020;14:149-61. [PMID: 31931636 DOI: 10.1080/17476348.2020.1700796] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
148 Li Y, Qian H, Yu K, Huang Y. Nonadherence in Home-Based Pulmonary Rehabilitation Program for COPD Patients. Can Respir J 2020;2020:5146765. [PMID: 31998425 DOI: 10.1155/2020/5146765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
149 McElvaney OF, Murphy MP, Reeves EP, McElvaney NG. Anti-cytokines as a Strategy in Alpha-1 Antitrypsin Deficiency. Chronic Obstr Pulm Dis 2020;7:203-13. [PMID: 32503090 DOI: 10.15326/jcopdf.7.3.2019.0171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
150 Ruiz-garcía A, Arranz-martínez E, García-álvarez JC, García-fernández ME, Palacios-martínez D, Montero-costa A, Ciria-de-pablo C, López-uriarte B, García-pliego RA, Chao-escuer P, Zafra-urango C, Alcaraz-bethencourt A, Redondo-de-pedro S, Escamilla-guijarro N, Pascual-val T, Vieira-pascual MC, Martínez-irazusta J, Martínez-cid-de-rivera E, Rodríguez-de-cossío Á, de-Prado-Prieto L, Adrián-sanz M, Minguela-puras ME, Blanco-canseco JM, Rubio-villar M, Berbil-bautista ML, Hueso-quesada R, Plata-barajas MT, Redondo-sánchez M, Durán-tejada MR, García-redondo MR, Sánchez-herráiz M, Rey-lópez AM, García-garcía-alcañiz MP, Abad-schilling C, Hidalgo-calleja Y, Rivera-teijido M. Prevalence of diabetes mellitus in Spanish primary care setting and its association with cardiovascular risk factors and cardiovascular diseases. SIMETAP-DM study. Clínica e Investigación en Arteriosclerosis (English Edition) 2020;32:15-25. [DOI: 10.1016/j.artere.2019.03.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
151 Anazawa R, Kawata N, Matsuura Y, Ikari J, Tada Y, Suzuki M, Takayanagi S, Matsuoka S, Matsushita S, Tatsumi K. Longitudinal changes in structural lung abnormalities using MDCT in chronic obstructive pulmonary disease with asthma-like features. PLoS One 2019;14:e0227141. [PMID: 31887184 DOI: 10.1371/journal.pone.0227141] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
152 Lortet-Tieulent J, Soerjomataram I, López-Campos JL, Ancochea J, Coebergh JW, Soriano JB. International trends in COPD mortality, 1995-2017. Eur Respir J 2019;54:1901791. [PMID: 31744832 DOI: 10.1183/13993003.01791-2019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
153 . Update on the Pathogenesis of COPD. N Engl J Med 2019;381:2483-4. [DOI: 10.1056/nejmc1914437] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
154 Ye W, Li X, Gu W, Guo X, Han F, Liu S. A comparison of diagnostic consistency for asthma-chronic obstructive pulmonary disease overlap and clinical characteristics study. BMC Pulm Med 2019;19:249. [PMID: 31852476 DOI: 10.1186/s12890-019-1024-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
155 Ko FWS, Sin DD. Twenty-five years of Respirology: Advances in COPD. Respirology 2020;25:17-9. [PMID: 31840889 DOI: 10.1111/resp.13734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
156 Dalon F, Devouassoux G, Belhassen M, Nachbaur G, Correia Da Silva C, Sail L, Jacoud F, Chouaid C, Van Ganse E. Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy. Int J Chron Obstruct Pulmon Dis 2019;14:2905-15. [PMID: 31908439 DOI: 10.2147/COPD.S222762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
157 Singh D, D'Urzo AD, Donohue JF, Kerwin EM, Molins E, Chuecos F, Ribera A, Jarreta D. An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD. Int J Chron Obstruct Pulmon Dis 2019;14:2835-48. [PMID: 31827323 DOI: 10.2147/COPD.S217710] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
158 Obeidat M, Faiz A, Li X, van den Berge M, Hansel NN, Joubert P, Hao K, Brandsma CA, Rafaels N, Mathias R, Ruczinski I, Beaty TH, Barnes KC, Man SFP, Paré PD, Sin DD. The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD. Eur Respir J 2019;54:1900521. [PMID: 31537701 DOI: 10.1183/13993003.00521-2019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
159 Sun XJ, He ZY. Macrolides for treatment of chronic obstructive pulmonary disease. Chin Med J (Engl) 2019;132:1261-3. [PMID: 30973449 DOI: 10.1097/CM9.0000000000000248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
160 Yang CX, Shi H, Ding I, Milne S, Hernandez Cordero AI, Yang CWT, Kim EK, Hackett TL, Leung J, Sin DD, Obeidat M. Widespread Sexual Dimorphism in the Transcriptome of Human Airway Epithelium in Response to Smoking. Sci Rep 2019;9:17600. [PMID: 31772224 DOI: 10.1038/s41598-019-54051-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
161 Suissa S, Dell'Aniello S, Ernst P. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice. Chest 2020;157:846-55. [PMID: 31759966 DOI: 10.1016/j.chest.2019.11.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
162 Milne S, Mannino D, Sin DD. Asthma-COPD Overlap and Chronic Airflow Obstruction: Definitions, Management, and Unanswered Questions. J Allergy Clin Immunol Pract 2020;8:483-95. [PMID: 31740296 DOI: 10.1016/j.jaip.2019.10.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
163 Mathioudakis AG, Janner J, Moberg M, Alonso-Coello P, Vestbo J. A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations. ERJ Open Res 2019;5:00136-2019. [PMID: 31754621 DOI: 10.1183/23120541.00136-2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
164 D'Urzo AD, Singh D, Donohue JF, Chapman KR. Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. Ther Adv Respir Dis 2019;13:1753466619850725. [PMID: 31096854 DOI: 10.1177/1753466619850725] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
165 Sawalha S, Hedman L, Backman H, Stenfors N, Rönmark E, Lundbäck B, Lindberg A. The impact of comorbidities on mortality among men and women with COPD: report from the OLIN COPD study. Ther Adv Respir Dis 2019;13:1753466619860058. [PMID: 31291820 DOI: 10.1177/1753466619860058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
166 Arnal JM, Saoli M, Garnero A. Airway and transpulmonary driving pressures and mechanical powers selected by INTELLiVENT-ASV in passive, mechanically ventilated ICU patients. Heart Lung 2020;49:427-34. [PMID: 31733881 DOI: 10.1016/j.hrtlng.2019.11.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
167 Genschmer KR, Russell DW, Lal C, Szul T, Bratcher PE, Noerager BD, Abdul Roda M, Xu X, Rezonzew G, Viera L, Dobosh BS, Margaroli C, Abdalla TH, King RW, McNicholas CM, Wells JM, Dransfield MT, Tirouvanziam R, Gaggar A, Blalock JE. Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung. Cell 2019;176:113-126.e15. [PMID: 30633902 DOI: 10.1016/j.cell.2018.12.002] [Cited by in Crossref: 125] [Cited by in F6Publishing: 134] [Article Influence: 41.7] [Reference Citation Analysis]
168 Li Q, Qu HJ, Lv D, Yeh MK, Sun S, Li L, Liao Y. Drug-related problems among hospitalized patients with COPD in mainland China. Int J Clin Pharm 2019;41:1507-15. [PMID: 31705457 DOI: 10.1007/s11096-019-00913-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
169 Labeix P, Berger M, Court Fortune I, Feasson L, Verges S, Costes F. Quadriceps Endurance Increases Following Cycling Exercise With Non-Invasive Ventilation In Moderate-To-Severe COPD Patients. A Non-Randomized Controlled Study. Int J Chron Obstruct Pulmon Dis 2019;14:2461-8. [PMID: 31806955 DOI: 10.2147/COPD.S216347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
170 Tanabe N, Shima H, Sato S, Oguma T, Kubo T, Kozawa S, Koizumi K, Sato A, Togashi K, Hirai T. Direct evaluation of peripheral airways using ultra-high-resolution CT in chronic obstructive pulmonary disease. European Journal of Radiology 2019;120:108687. [DOI: 10.1016/j.ejrad.2019.108687] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
171 Lea S, Metryka A, Li J, Higham A, Bridgewood C, Villetti G, Civelli M, Facchinetti F, Singh D. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients. Cytokine 2019;123:154739. [DOI: 10.1016/j.cyto.2019.154739] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
172 Sun Y, Milne S, Jaw JE, Yang CX, Xu F, Li X, Obeidat M, Sin DD. BMI is associated with FEV1 decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials. Respir Res 2019;20:236. [PMID: 31665000 DOI: 10.1186/s12931-019-1209-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
173 Olschewski H, Canepa M, Kovacs G. Pulmonary and cardiac drugs: clinically relevant interactions. Herz 2019;44:517-21. [PMID: 31297545 DOI: 10.1007/s00059-019-4834-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
174 Reddi BA, Johnston SD, Bart S, Chan JC, Finnis M. Abnormal pulmonary function tests are associated with prolonged ventilation and risk of complications following elective cardiac surgery. Anaesth Intensive Care 2019;47:510-5. [DOI: 10.1177/0310057x19877188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
175 Kolsum U, Southworth T, Jackson N, Singh D. Blood eosinophil counts in COPD patients compared to controls. Eur Respir J 2019;54:1900633. [PMID: 31221811 DOI: 10.1183/13993003.00633-2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
176 Tracey L, Lewthwaite H, Abdallah SJ, Murray S, Wilkinson-Maitland CA, Donovan A, Maltais F, O'Donnell DE, Bourbeau J, Smith BM, Jensen D; Canadian Respiratory Research Network (CRRN). Physiological and perceptual responses to exercise according to locus of symptom limitation in COPD. Respir Physiol Neurobiol 2020;273:103322. [PMID: 31629879 DOI: 10.1016/j.resp.2019.103322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
177 Bourbeau J, Bhutani M, Hernandez P, Aaron SD, Balter M, Beauchesne M, D’urzo A, Goldstein R, Kaplan A, Maltais F, Sin DD, Marciniuk DD. Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 2019;3:210-32. [DOI: 10.1080/24745332.2019.1668652] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
178 Nascimento FABD, Silva GPFD, Prudente GFG, Mesquita R, Pereira EDB. Assessment of religious coping in patients with COPD. J Bras Pneumol 2019;46:e20180150. [PMID: 31644700 DOI: 10.1590/1806-3713/e20180150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Königsdorfer N, Jörres RA, Söhler S, Welte T, Behr J, Ficker JH, Bals R, Watz H, Lutter JI, Lucke T, Biertz F, Alter P, Vogelmeier CF, Kahnert K. Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort. Patient Prefer Adherence 2019;13:1711-21. [PMID: 31631986 DOI: 10.2147/PPA.S223438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
180 Bellou V, Belbasis L, Konstantinidis AK, Tzoulaki I, Evangelou E. Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal. BMJ 2019;367:l5358. [PMID: 31585960 DOI: 10.1136/bmj.l5358] [Cited by in Crossref: 27] [Cited by in F6Publishing: 55] [Article Influence: 9.0] [Reference Citation Analysis]
181 Zhu A, Teng Y, Ge D, Zhang X, Hu M, Yao X. Role of metformin in treatment of patients with chronic obstructive pulmonary disease: a systematic review. J Thorac Dis 2019;11:4371-8. [PMID: 31737323 DOI: 10.21037/jtd.2019.09.84] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
182 Yoon HI, Sin DD. COPD in China: From Crisis to Hope…. Chest 2018;154:474-5. [PMID: 30195339 DOI: 10.1016/j.chest.2018.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
183 Szentes BL, Schwarzkopf L, Kirsch F, Schramm A, Leidl R. Measuring quality of life in COPD patients: comparing disease-specific supplements to the EQ-5D-5L. Expert Rev Pharmacoecon Outcomes Res 2020;20:523-9. [PMID: 31512524 DOI: 10.1080/14737167.2019.1662302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
184 Zhang H, Qiu SL, Tang QY, Zhou X, Zhang JQ, He ZY, Bai J, Li MH, Deng JM, Liang Y, Zhong XN. Erythromycin suppresses neutrophil extracellular traps in smoking-related chronic pulmonary inflammation. Cell Death Dis 2019;10:678. [PMID: 31515489 DOI: 10.1038/s41419-019-1909-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
185 Gagné M, Lauzier S, Babineau-Therrien J, Hamel C, Penney SE, Bourbeau J, Moisan J, Boulet LP. COPD-Specific Self-Management Support Provided by Trained Educators in Everyday Practice is Associated with Improved Quality of Life, Health-Directed Behaviors, and Skill and Technique Acquisition: A Convergent Embedded Mixed-Methods Study. Patient 2020;13:103-19. [PMID: 31502238 DOI: 10.1007/s40271-019-00386-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
186 Lebron ISL, da Silva LF, Paletta JT, da Silva RA, Sant'Ana M, Costa SS, Iyomasa-Pilon MM, Souza HR, Possebon L, Girol AP. Modulation of the endogenous Annexin A1 in a cigarette smoke cessation model: Potential therapeutic target in reversing the damage caused by smoking? Pathol Res Pract 2019;215:152614. [PMID: 31500927 DOI: 10.1016/j.prp.2019.152614] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
187 Gomes S, Cavadas B, Ferreira JC, Marques PI, Monteiro C, Sucena M, Sousa C, Vaz Rodrigues L, Teixeira G, Pinto P, Tavares de Abreu T, Bárbara C, Semedo J, Mota L, Carvalho AS, Matthiesen R, Pereira L, Seixas S. Profiling of lung microbiota discloses differences in adenocarcinoma and squamous cell carcinoma. Sci Rep 2019;9:12838. [PMID: 31492894 DOI: 10.1038/s41598-019-49195-w] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
188 Tong H, Liu Y, Zhu Y, Zhang B, Hu J. The therapeutic effects of qigong in patients with chronic obstructive pulmonary disease in the stable stage: a meta-analysis. BMC Complement Altern Med 2019;19:239. [PMID: 31484521 DOI: 10.1186/s12906-019-2639-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
189 Janaudis-ferreira T, Tansey CM, Harrison SL, Beaurepaire CE, Goodridge D, Bourbeau J, Baltzan M. A Qualitative Study to Inform a More Acceptable Pulmonary Rehabilitation Program after Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Annals ATS 2019;16:1158-64. [DOI: 10.1513/annalsats.201812-854oc] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
190 Zhang Y, Gao J, Luo Y. The effect of various durations of cigarette smoke exposure on muscle fibre remodeling in rat diaphragms. Biomedicine & Pharmacotherapy 2019;117:109053. [DOI: 10.1016/j.biopha.2019.109053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
191 Voorham J, Corradi M, Papi A, Vogelmeier CF, Singh D, Fabbri LM, Kerkhof M, Kocks JH, Carter V, Price D. Comparative effectiveness of triple therapy versus dual bronchodilation in COPD. ERJ Open Res 2019;5:00106-2019. [PMID: 31497610 DOI: 10.1183/23120541.00106-2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
192 Geidl W, Carl J, Cassar S, Lehbert N, Mino E, Wittmann M, Wagner R, Schultz K, Pfeifer K. Physical Activity and Sedentary Behaviour Patterns in 326 Persons with COPD before Starting a Pulmonary Rehabilitation: A Cluster Analysis. J Clin Med 2019;8:E1346. [PMID: 31470678 DOI: 10.3390/jcm8091346] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
193 Dalon F, Roche N, Belhassen M, Nolin M, Pegliasco H, Deslée G, Housset B, Devillier P, Van Ganse E. Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study. Int J Chron Obstruct Pulmon Dis 2019;14:1839-54. [PMID: 31692478 DOI: 10.2147/COPD.S214061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
194 Roche N, Antoniadis A, Hess D, Li PZ, Kelkel E, Leroy S, Pison C, Burgel PR, Aguilaniu B; COLIBRI COPD Research Group. Are there specific clinical characteristics associated with physician's treatment choices in COPD? Respir Res 2019;20:189. [PMID: 31429756 DOI: 10.1186/s12931-019-1156-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
195 Stolz D, Hirsch HH, Schilter D, Louis R, Rakic J, Boeck L, Papakonstantinou E, Schindler C, Grize L, Tamm M. Intensified Therapy with Inhaled Corticosteroids and Long-Acting β2-Agonists at the Onset of Upper Respiratory Tract Infection to Prevent Chronic Obstructive Pulmonary Disease Exacerbations. A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med 2018;197:1136-46. [PMID: 29266965 DOI: 10.1164/rccm.201709-1807OC] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
196 Mkorombindo T, Dransfield MT. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2019;14:1779-87. [PMID: 31496677 DOI: 10.2147/COPD.S162781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
197 Newby PR, Crossley D, Crisford H, Stockley JA, Mumford RA, Carter RI, Bolton CE, Hopkinson NS, Mahadeva R, Steiner MC, Wilkinson TMA, Sapey E, Stockley RA. A specific proteinase 3 activity footprint in α1-antitrypsin deficiency. ERJ Open Res 2019;5:00095-2019. [PMID: 31403052 DOI: 10.1183/23120541.00095-2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
198 Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J 2019;54:1900651. [PMID: 31073084 DOI: 10.1183/13993003.00651-2019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
199 Le LAK, Johannessen A, Hardie JA, Johansen OE, Gulsvik A, Vikse BE, Bakke P. Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort. Int J Chron Obstruct Pulmon Dis 2019;14:1639-55. [PMID: 31413559 DOI: 10.2147/COPD.S194019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
200 Cortegiani A, Longhini F, Carlucci A, Scala R, Groff P, Bruni A, Garofalo E, Taliani MR, Maccari U, Vetrugno L, Lupia E, Misseri G, Comellini V, Giarratano A, Nava S, Navalesi P, Gregoretti C. High-flow nasal therapy versus noninvasive ventilation in COPD patients with mild-to-moderate hypercapnic acute respiratory failure: study protocol for a noninferiority randomized clinical trial. Trials 2019;20:450. [PMID: 31331372 DOI: 10.1186/s13063-019-3514-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
201 Soumagne T, Guillien A, Roux P, Laplante JJ, Botebol M, Laurent L, Roche N, Dalphin JC, Degano B. Quantitative and qualitative evaluation of spirometry for COPD screening in general practice. Respir Med Res 2020;77:31-6. [PMID: 32035336 DOI: 10.1016/j.resmer.2019.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
202 Csoma B, Bikov A, Nagy L, Tóth B, Tábi T, Szűcs G, Komlósi ZI, Müller V, Losonczy G, Lázár Z. Dysregulation of the endothelial nitric oxide pathway is associated with airway inflammation in COPD. Respir Res 2019;20:156. [PMID: 31311549 DOI: 10.1186/s12931-019-1133-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
203 Trudzinski FC, Alqudrah M, Omlor A, Zewinger S, Fliser D, Speer T, Seiler F, Biertz F, Koch A, Vogelmeier C, Welte T, Watz H, Waschki B, Fähndrich S, Jörres R, Bals R; German COSYCONET consortium. Consequences of chronic kidney disease in chronic obstructive pulmonary disease. Respir Res 2019;20:151. [PMID: 31299972 DOI: 10.1186/s12931-019-1107-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
204 Singh D, D'Urzo AD, Donohue JF, Kerwin EM. Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective. Respir Res 2019;20:141. [PMID: 31286970 DOI: 10.1186/s12931-019-1108-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
205 Opina MTD, Nicklas BJ, Lovato JF, Files DC, Kritchevsky SB, Moore WC. Association of Symptoms of Obstructive Lung Disease and All-Cause Mortality in Older Adult Smokers. J Am Geriatr Soc 2019;67:2116-22. [PMID: 31250432 DOI: 10.1111/jgs.16052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
206 Boehm A, Pizzini A, Sonnweber T, Loeffler-Ragg J, Lamina C, Weiss G, Tancevski I. Assessing global COPD awareness with Google Trends. Eur Respir J 2019;53:1900351. [PMID: 31097517 DOI: 10.1183/13993003.00351-2019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
207 Trudzinski FC, Kahnert K, Vogelmeier CF, Alter P, Seiler F, Fähndrich S, Watz H, Welte T, Speer T, Zewinger S, Biertz F, Kauczor HU, Jörres RA, Bals R; COSYCONET consortium. Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort. Respir Med 2019;154:18-26. [PMID: 31203096 DOI: 10.1016/j.rmed.2019.06.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
208 Seijo LM, Soriano JB, Peces-Barba G. New evidence on the chemoprevention of inhaled steroids and the risk of lung cancer in COPD. Eur Respir J 2019;53:1900717. [PMID: 31167885 DOI: 10.1183/13993003.00717-2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
209 Vanfleteren LEGW, Boonen LMC, Spruit MA, Janssen DJA, Wouters EFM, Franssen FME. The superexacerbator phenotype in patients with COPD: a descriptive analysis. ERJ Open Res 2019;5:00235-2018. [PMID: 31192249 DOI: 10.1183/23120541.00235-2018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
210 Troosters T, Blondeel A, Rodrigues FM, Janssens W, Demeyer H. Strategies to Increase Physical Activity in Chronic Respiratory Diseases. Clinics in Chest Medicine 2019;40:397-404. [DOI: 10.1016/j.ccm.2019.02.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
211 Calzetta L, Rogliani P, Page C, Rinaldi B, Cazzola M, Matera MG. Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. Pulmonary Pharmacology & Therapeutics 2019;56:39-50. [DOI: 10.1016/j.pupt.2019.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
212 Ruiz-García A, Arranz-Martínez E, García-Álvarez JC, García-Fernández ME, Palacios-Martínez D, Montero-Costa A, Ciria-de-Pablo C, López-Uriarte B, García-Pliego RA, Chao-Escuer P, Zafra-Urango C, Alcaraz-Bethencourt A, Redondo-de-Pedro S, Escamilla-Guijarro N, Pascual-Val T, Vieira-Pascual MC, Martínez-Irazusta J, Martínez-Cid-de-Rivera E, Rodríguez-de-Cossío Á, de-Prado-Prieto L, Adrián-Sanz M, Minguela-Puras ME, Blanco-Canseco JM, Rubio-Villar M, Berbil-Bautista ML, Hueso-Quesada R, Plata-Barajas MT, Redondo-Sánchez M, Durán-Tejada MR, García-Redondo MR, Sánchez-Herráiz M, Rey-López AM, García-García-Alcañiz MP, Abad-Schilling C, Hidalgo-Calleja Y, Rivera-Teijido M; En representación del Grupo de Investigación del Estudio SIMETAP. Grupo de Investigación del Estudio SIMETAP:. Prevalence of diabetes mellitus in Spanish primary care setting and its association with cardiovascular risk factors and cardiovascular diseases. SIMETAP-DM study. Clin Investig Arterioscler 2020;32:15-26. [PMID: 31130360 DOI: 10.1016/j.arteri.2019.03.006] [Reference Citation Analysis]
213 Singh D, Fabbri LM, Corradi M, Georges G, Guasconi A, Vezzoli S, Petruzzelli S, Papi A. Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. Eur Respir J 2019;53:1900235. [PMID: 30792343 DOI: 10.1183/13993003.00235-2019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
214 Carette H, Zysman M, Morelot-Panzini C, Perrin J, Gomez E, Guillaumot A, Burgel PR, Deslee G, Surpas P, Le Rouzic O, Perez T, Chaouat A, Roche N, Chabot F; Initiatives BPCO (bronchopneumopathie chronique obstructive) Scientific Committee and Investigators. Prevalence and management of chronic breathlessness in COPD in a tertiary care center. BMC Pulm Med 2019;19:95. [PMID: 31096982 DOI: 10.1186/s12890-019-0851-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
215 Liu J, Liu J, Zou Y. Relationship between neutrophil-lymphocyte ratio and short-term prognosis in the chronic obstructive pulmonary patients with acute exacerbation. Biosci Rep 2019;39:BSR20190675. [PMID: 31015366 DOI: 10.1042/BSR20190675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
216 Mathioudakis AG, Moberg M, Janner J, Alonso-Coello P, Vestbo J. Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials. ERJ Open Res 2019;5:00072-2019. [PMID: 31111041 DOI: 10.1183/23120541.00072-2019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
217 Hiemstra PS. Macrophage function in chronic obstructive pulmonary disease: The many faces of notch signalling. EBioMedicine 2019;43:22-3. [PMID: 31047859 DOI: 10.1016/j.ebiom.2019.04.035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
218 Triest FJJ, Franssen FME, Reynaert N, Gaffron S, Spruit MA, Janssen DJA, Rutten EPA, Wouters EFM, Vanfleteren LEGW. Disease-Specific Comorbidity Clusters in COPD and Accelerated Aging. J Clin Med 2019;8:E511. [PMID: 31013986 DOI: 10.3390/jcm8040511] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
219 Topalovic M, Das N, Burgel PR, Daenen M, Derom E, Haenebalcke C, Janssen R, Kerstjens HAM, Liistro G, Louis R, Ninane V, Pison C, Schlesser M, Vercauter P, Vogelmeier CF, Wouters E, Wynants J, Janssens W; Pulmonary Function Study Investigators., Pulmonary Function Study Investigators:. Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests. Eur Respir J 2019;53:1801660. [PMID: 30765505 DOI: 10.1183/13993003.01660-2018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 42] [Article Influence: 10.7] [Reference Citation Analysis]
220 Obeidat M, Sadatsafavi M, Sin DD. Precision health: treating the individual patient with chronic obstructive pulmonary disease. Med J Aust 2019;210:424-8. [PMID: 30977152 DOI: 10.5694/mja2.50138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
221 Surani S, Aiyer A, Eikermann S, Murphy T, Anand P, Varon J, Vanderheiden D, Khan A, Guzman A. Adoption and adherence to chronic obstructive pulmonary disease GOLD guidelines in a primary care setting. SAGE Open Med 2019;7:2050312119842221. [PMID: 31057794 DOI: 10.1177/2050312119842221] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
222 Pérez-Bogerd S, Michils A, Malinovschi A, Van Muylem A. COPD patients with peripheral airway obstruction reversibility identified by exhaled nitric oxide. J Breath Res 2019;13:036002. [PMID: 30802891 DOI: 10.1088/1752-7163/ab0a14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Alter P, Watz H, Kahnert K, Rabe KF, Biertz F, Fischer R, Jung P, Graf J, Bals R, Vogelmeier CF, Jörres RA. Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD. Respir Res 2019;20:61. [PMID: 30917825 DOI: 10.1186/s12931-019-1025-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
224 Zimmermann SC, Tonga KO, Thamrin C. Dismantling airway disease with the use of new pulmonary function indices. Eur Respir Rev 2019;28:180122. [PMID: 30918023 DOI: 10.1183/16000617.0122-2018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
225 Qi X, Chen H, Fu B, Huang Z, Mou Y, Liu J, Xu Y, Xiong W, Cao Y. LncRNAs NR-026690 and ENST00000447867 are upregulated in CD4+ T cells in patients with acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis 2019;14:699-711. [PMID: 30988604 DOI: 10.2147/COPD.S191815] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
226 Suissa S, Dell'Aniello S, Ernst P. Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice. Chest 2019;155:1158-65. [PMID: 30922950 DOI: 10.1016/j.chest.2019.03.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
227 Schleich F, Bikov A, Mathioudakis AG, McDonnell M, Andersson C, Bonini M, Uller L, Idzko M, Singh D, Lopez-Campos JL, Bossios A, Adcock IM, Usmani O, Spanevello A, Bonvini SJ. Research highlights from the 2018 European Respiratory Society International Congress: airway disease. ERJ Open Res 2019;5:00225-2018. [PMID: 30895184 DOI: 10.1183/23120541.00225-2018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
228 Crim C, Watkins ML, Bateman ED, Feldman GJ, Schenkenberger I, Kerwin EM, Crawford C, Pudi K, Ho S, Baidoo C, Castro-Santamaria R. Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD. Int J Chron Obstruct Pulmon Dis 2019;14:615-29. [PMID: 30880951 DOI: 10.2147/COPD.S190603] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
229 Sorathia L. Palliative Care in Chronic Obstructive Pulmonary Disease. Med Clin North Am 2019;103:517-26. [PMID: 30955518 DOI: 10.1016/j.mcna.2018.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
230 Aramburu A, Arostegui I, Moraza J, Barrio I, Aburto M, García-Loizaga A, Uranga A, Zabala T, Quintana JM, Esteban C. COPD classification models and mortality prediction capacity. Int J Chron Obstruct Pulmon Dis 2019;14:605-13. [PMID: 30880950 DOI: 10.2147/COPD.S184695] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
231 Shapira U, Krubiner M, Ehrenwald M, Shapira I, Zeltser D, Berliner S, Rogowski O, Shenhar-Tsarfaty S, Bar-Shai A. Eosinophil levels predict lung function deterioration in apparently healthy individuals. Int J Chron Obstruct Pulmon Dis 2019;14:597-603. [PMID: 30880949 DOI: 10.2147/COPD.S192594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
232 Higham A, Quinn AM, Cançado JED, Singh D. The pathology of small airways disease in COPD: historical aspects and future directions. Respir Res 2019;20:49. [PMID: 30832670 DOI: 10.1186/s12931-019-1017-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 70] [Article Influence: 15.7] [Reference Citation Analysis]
233 Tam A, Hughes M, McNagny KM, Obeidat M, Hackett TL, Leung JM, Shaipanich T, Dorscheid DR, Singhera GK, Yang CWT, Paré PD, Hogg JC, Nickle D, Sin DD. Hedgehog signaling in the airway epithelium of patients with chronic obstructive pulmonary disease. Sci Rep 2019;9:3353. [PMID: 30833624 DOI: 10.1038/s41598-019-40045-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
234 Moon J, Sin DD. Inhaled corticosteroids and fractures in chronic obstructive pulmonary disease: current understanding and recommendations. Current Opinion in Pulmonary Medicine 2019;25:165-72. [DOI: 10.1097/mcp.0000000000000554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
235 Gutberlet M, Kaireit TF, Voskrebenzev A, Kern AL, Obert A, Wacker F, Hohlfeld JM, Vogel-Claussen J. Repeatability of Regional Lung Ventilation Quantification Using Fluorinated (19F) Gas Magnetic Resonance Imaging. Acad Radiol 2019;26:395-403. [PMID: 30472224 DOI: 10.1016/j.acra.2018.10.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
236 Böcskei RM, Benczúr B, Losonczy G, Illyés M, Cziráki A, Müller V, Bohács A, Bikov A. Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD. Lung 2019;197:189-97. [PMID: 30820636 DOI: 10.1007/s00408-019-00211-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
237 Feng HR, Zhang C, Ying SM. Classical and Emerging Therapies against Chronic Obstructive Pulmonary Disease. Chin Med J (Engl) 2018;131:1894-7. [PMID: 30082518 DOI: 10.4103/0366-6999.238133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
238 Lee J, Kim HS. The Role of Autophagy in Eosinophilic Airway Inflammation. Immune Netw 2019;19:e5. [PMID: 30838160 DOI: 10.4110/in.2019.19.e5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
239 Rogliani P, Calzetta L, Matera MG, di Daniele N, Girolami A, Cazzola M, Ora J. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother 2019;20:737-50. [PMID: 30707637 DOI: 10.1080/14656566.2019.1570133] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
240 Wells JM, Colangelo LA, Sivarajan L, Thyagarajan B, Dransfield MT, Iribarren C, Reyfman PA, Jacobs DR, Washko GR, Kalhan R. Inflammation and endothelial activation in early adulthood are associated with future emphysema: the CARDIA Lung Study. Eur Respir J 2019;53:1801532. [PMID: 30464011 DOI: 10.1183/13993003.01532-2018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
241 Calzetta L, Cazzola M, Matera MG, Rogliani P. Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD. Chest 2019;155:758-70. [PMID: 30660781 DOI: 10.1016/j.chest.2018.12.016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 15.3] [Reference Citation Analysis]
242 Xie S, Wang K, Zhang W, Xiao K, Yan P, Li Y, He W, Zhang Y, Xie L. Immunodeficiency in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Inflammation 2018;41:1582-9. [PMID: 30047000 DOI: 10.1007/s10753-018-0830-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
243 Su Y, Luo H, Yang J. Heparin-binding EGF-like growth factor attenuates lung inflammation and injury in a murine model of pulmonary emphysema. Growth Factors 2019;36:246-62. [DOI: 10.1080/08977194.2018.1552270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
244 Make BJ. COPD: A New Diagnostic Paradigm. Chronic Obstr Pulm Dis 2019;6:438-43. [PMID: 31710800 DOI: 10.15326/jcopdf.6.5.2019.0172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
245 Crisafulli E, Ielpo A, Barbeta E, Ceccato A, Huerta A, Gabarrús A, Soler N, Chetta A, Torres A. Clinical variables predicting the risk of a hospital stay for longer than 7 days in patients with severe acute exacerbations of chronic obstructive pulmonary disease: a prospective study. Respir Res 2018;19:261. [PMID: 30591055 DOI: 10.1186/s12931-018-0951-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
246 Suissa S, Ariel A. Triple therapy trials in COPD: a precision medicine opportunity. Eur Respir J 2018;52:1801848. [PMID: 30545959 DOI: 10.1183/13993003.01848-2018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
247 Leung JM, Sin DD. Inhaled corticosteroids in COPD: the final verdict is…. Eur Respir J 2018;52:1801940. [PMID: 30545961 DOI: 10.1183/13993003.01940-2018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
248 Cazzola M, Rogliani P, Calzetta L, Matera MG. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J 2018;52:1801586. [PMID: 30309975 DOI: 10.1183/13993003.01586-2018] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 17.8] [Reference Citation Analysis]
249 Flynn RWV, MacDonald TM, Chalmers JD, Schembri S. The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD. Respir Res 2018;19:249. [PMID: 30541559 DOI: 10.1186/s12931-018-0960-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
250 Fernandes FLA, Cukier A, Camelier AA, Fritscher CC, Costa CHD, Pereira EDB, Godoy I, Cançado JED, Romaldini JG, Chatkin JM, Jardim JR, Rabahi MF, Nucci MCNM, Sales MDPU, Castellano MVCO, Aidé MA, Teixeira PJZ, Maciel R, Corrêa RA, Stirbulov R, Athanazio RA, Russo R, Minamoto ST, Lundgren FLC. Recommendations for the pharmacological treatment of COPD: questions and answers. J Bras Pneumol 2017;43:290-301. [PMID: 29365005 DOI: 10.1590/S1806-37562017000000153] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
251 Trethewey SP, Edgar RG, Turner AM, Mukherjee R. Ward-Based Non-Invasive Ventilation in Acute Exacerbations of COPD: A Narrative Review of Current Practice and Outcomes in the UK. Healthcare (Basel) 2018;6:E145. [PMID: 30544857 DOI: 10.3390/healthcare6040145] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
252 Soriano JB, Polverino F, Cosio BG. What is early COPD and why is it important? Eur Respir J 2018;52:1801448. [PMID: 30309976 DOI: 10.1183/13993003.01448-2018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 8.3] [Reference Citation Analysis]
253 Jamieson KC, Traves SL, Kooi C, Wiehler S, Dumonceaux CJ, Maciejewski BA, Arnason JW, Michi AN, Leigh R, Proud D. Rhinovirus and Bacteria Synergistically Induce IL-17C Release from Human Airway Epithelial Cells To Promote Neutrophil Recruitment. J Immunol 2019;202:160-70. [PMID: 30504421 DOI: 10.4049/jimmunol.1800547] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
254 Barrera C, Rocchi S, Degano B, Soumagne T, Laurent L, Bellanger A, Laplante J, Millon L, Dalphin J, Reboux G. Microbial exposure to dairy farmers’ dwellings and COPD occurrence. International Journal of Environmental Health Research 2019;29:387-99. [DOI: 10.1080/09603123.2018.1545900] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
255 Xu W, Li R, Guan L, Wang K, Hu Y, Xu L, Zhou L, Chen R, Chen X. Combination of inspiratory and expiratory muscle training in same respiratory cycle versus different cycles in COPD patients: a randomized trial. Respir Res 2018;19:225. [PMID: 30458805 DOI: 10.1186/s12931-018-0917-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
256 Chalmers JD, Djamin RS, Schouten M, Keir HR, Tan B, Aerts JGJV, Huang JT, van der Eerden M. Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial. ERJ Open Res 2018;4:00136-2018. [PMID: 30443554 DOI: 10.1183/23120541.00136-2018] [Reference Citation Analysis]
257 Mortensen J, Berg RMG. Lung Scintigraphy in COPD. Semin Nucl Med 2019;49:16-21. [PMID: 30545511 DOI: 10.1053/j.semnuclmed.2018.10.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
258 Blanchard E, Piquet J, Piperno D, Pinet C, Stach B, Roche N. [Vaccination of COPD patients: From guidelines to routine practise]. Rev Mal Respir 2018;35:999-1001. [PMID: 30429091 DOI: 10.1016/j.rmr.2018.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
259 Scrutinio D, Guida P, Passantino A, Ammirati E, Oliva F, Lagioia R, Raimondo R, Venezia M, Frigerio M. Acutely decompensated heart failure with chronic obstructive pulmonary disease: Clinical characteristics and long-term survival. Eur J Intern Med 2019;60:31-8. [PMID: 30446355 DOI: 10.1016/j.ejim.2018.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
260 Pirina P, Zinellu E, Paliogiannis P, Fois AG, Marras V, Sotgia S, Carru C, Zinellu A. Circulating serotonin levels in COPD patients: a pilot study. BMC Pulm Med 2018;18:167. [PMID: 30409142 DOI: 10.1186/s12890-018-0730-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
261 Cazzola M, Page C. An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD. Eur Respir J 2018;52:1801675. [DOI: 10.1183/13993003.01675-2018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
262 Amatngalim GD, Hiemstra PS. Airway Epithelial Cell Function and Respiratory Host Defense in Chronic Obstructive Pulmonary Disease. Chin Med J (Engl) 2018;131:1099-107. [PMID: 29692382 DOI: 10.4103/0366-6999.230743] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
263 Voorham J, Roche N, Benhaddi H, van der Tol M, Carter V, van Boven JFM, Bjermer L, Miravitlles M, Price DB. Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK. BMJ Open 2018;8:e022051. [PMID: 30368448 DOI: 10.1136/bmjopen-2018-022051] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
264 Polastri M, Ambrosino N, Vitacca M, Nava S, Clini EM. Assessment of Symptoms in Patients with COPD: Strengths and Limitations of Clinical Scores. Curr Pulmonol Rep 2018;7:220-2. [DOI: 10.1007/s13665-018-0217-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
265 Smith BM, Jensen D, Brosseau M, Benedetti A, Coxson HO, Bourbeau J. Impact of pulmonary emphysema on exercise capacity and its physiological determinants in chronic obstructive pulmonary disease. Sci Rep 2018;8:15745. [PMID: 30356114 DOI: 10.1038/s41598-018-34014-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
266 Barjaktarevic I, Kaner R, Buhr RG, Cooper CB. Bronchodilator responsiveness or reversibility in asthma and COPD - a need for clarity. Int J Chron Obstruct Pulmon Dis 2018;13:3511-3. [PMID: 30498341 DOI: 10.2147/COPD.S183736] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
267 Pang H, Wang L, Liu J, Wang S, Yang Y, Yang T, Wang C. The prevalence and risk factors of venous thromboembolism in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease. Clin Respir J 2018;12:2573-80. [PMID: 30207643 DOI: 10.1111/crj.12959] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
268 Mathioudakis AG, Janjua S, Normansell R, Vestbo J; Cochrane Airways Group. Biomarkers to guide antibiotic therapy for COPD exacerbations. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013148] [Reference Citation Analysis]
269 Singh D. Double combination inhalers in COPD: How to get your head around this data. Respirology 2018;23:1088-9. [DOI: 10.1111/resp.13422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
270 Roche N, Martin C, Burgel PR. [Personalised COPD care: Where are we going?]. Rev Pneumol Clin 2018;74:315-26. [PMID: 30316649 DOI: 10.1016/j.pneumo.2018.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
271 Matera MG, Rinaldi B, Page C, Rogliani P, Cazzola M. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Metabolism & Toxicology 2018;14:1101-11. [DOI: 10.1080/17425255.2018.1530215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
272 Roversi S, Boschetto P, Beghe' B, Schito M, Garofalo M, Stendardo M, Ruggieri V, Tonelli R, Fucili A, D'Amico R, Banchelli F, Fabbri LM, Clini EM. Breathlessness, but not cough, suggests chronic obstructive pulmonary disease in elderly smokers with stable heart failure. Multidiscip Respir Med 2018;13:35. [PMID: 30305900 DOI: 10.1186/s40248-018-0148-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
273 Yu D, Liu X, Zhang G, Ming Z, Wang T. Isoliquiritigenin Inhibits Cigarette Smoke-Induced COPD by Attenuating Inflammation and Oxidative Stress via the Regulation of the Nrf2 and NF-κB Signaling Pathways. Front Pharmacol 2018;9:1001. [PMID: 30294270 DOI: 10.3389/fphar.2018.01001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
274 van Kampen SC, Jones R, Kisembo H, Houben RMGJ, Wei Y, Mugabe FR, Rutebemberwa E, Kirenga B. Chronic Respiratory Symptoms and Lung Abnormalities Among People With a History of Tuberculosis in Uganda: A National Survey. Clinical Infectious Diseases 2019;68:1919-25. [DOI: 10.1093/cid/ciy795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
275 Ferguson GT, Papi A, Anzueto A, Kerwin EM, Cappelletti C, Duncan EA, Nyberg J, Dorinsky P. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. Eur Respir J 2018;52:1801334. [PMID: 30220648 DOI: 10.1183/13993003.01334-2018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
276 Polverino E, Dimakou K, Hurst J, Martinez-Garcia MA, Miravitlles M, Paggiaro P, Shteinberg M, Aliberti S, Chalmers JD. The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. Eur Respir J 2018;52:1800328. [PMID: 30049739 DOI: 10.1183/13993003.00328-2018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 63] [Article Influence: 12.3] [Reference Citation Analysis]
277 Roversi S, Tonelli R, Beghè B, Banchelli F, D'Amico R, Malerba M, Fabbri LM, Clini EM. Use of adjunct cardiovascular therapy in patients hospitalised for acute exacerbations of COPD. ERJ Open Res 2018;4:00087-2018. [PMID: 30221169 DOI: 10.1183/23120541.00087-2018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
278 Boaventura R, Sibila O, Agusti A, Chalmers JD. Treatable traits in bronchiectasis. Eur Respir J 2018;52:1801269. [DOI: 10.1183/13993003.01269-2018] [Cited by in Crossref: 36] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
279 Ronit A, Benfield T, Mocroft A, Gerstoft J, Nordestgaard BG, Vestbo J, Nielsen SD; Copenhagen Co-morbidity in HIV Infection (COCOMO) Study Group. Diagnostic performance of clinical characteristics to detect airflow limitation in people living with HIV and in uninfected controls. HIV Med 2018;19:751-5. [PMID: 30160344 DOI: 10.1111/hiv.12669] [Reference Citation Analysis]
280 Alter P, Rabe KF, Schulz H, Vogelmeier CF, Jörres RA. Influence of body mass on predicted values of static hyperinflation in COPD. Int J Chron Obstruct Pulmon Dis 2018;13:2551-5. [PMID: 30197511 DOI: 10.2147/COPD.S164096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
281 Milne S, Sin DD. What triggers acute exacerbations of COPD? Why not ask the patient! Respirology 2019;24:7-8. [PMID: 30106196 DOI: 10.1111/resp.13384] [Reference Citation Analysis]
282 Singh D. Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2018;19:1279-87. [PMID: 29985096 DOI: 10.1080/14656566.2018.1498841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
283 Cuthbert JJ, Kearsley JW, Kazmi S, Kallvikbakka-Bennett A, Weston J, Davis J, Rimmer S, Clark AL. The impact of heart failure and chronic obstructive pulmonary disease on mortality in patients presenting with breathlessness. Clin Res Cardiol 2019;108:185-93. [PMID: 30091083 DOI: 10.1007/s00392-018-1342-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
284 Jones R, Muyinda H, Nyakoojo G, Kirenga B, Katagira W, Pooler J. Does pulmonary rehabilitation alter patients' experiences of living with chronic respiratory disease? A qualitative study. Int J Chron Obstruct Pulmon Dis 2018;13:2375-85. [PMID: 30122917 DOI: 10.2147/COPD.S165623] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
285 De Benedetto F, Pastorelli R, Ferrario M, de Blasio F, Marinari S, Brunelli L, Wouters EFM, Polverino F, Celli BR; Interdisciplinary Association for Research in Lung Disease (AIMAR) Study Group. Supplementation with Qter® and Creatine improves functional performance in COPD patients on long term oxygen therapy. Respir Med 2018;142:86-93. [PMID: 30170808 DOI: 10.1016/j.rmed.2018.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
286 Polastri M, Clini E, Nava S, Vitacca M, Ambrosino N. Evaluation of health-related quality of life in pulmonary diseases. International Journal of Therapy and Rehabilitation 2018;25:380-1. [DOI: 10.12968/ijtr.2018.25.8.380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
287 Culver BH. Assessment of severity and prognosis in COPD: moving beyond percent of predicted. Eur Respir J 2018;52:1801005. [PMID: 30072543 DOI: 10.1183/13993003.01005-2018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
288 Faner R, Noell G, Badia JR, López-giraldo A, Bakke P, Silverman EK, Tal-singer R, Agustí A. Distribution, temporal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort. Respiratory Medicine 2018;141:14-9. [DOI: 10.1016/j.rmed.2018.06.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
289 Valipour A. Valve therapy in patients with emphysematous type of chronic obstructive pulmonary disease (COPD): from randomized trials to patient selection in clinical practice. J Thorac Dis. 2018;10:S2780-S2796. [PMID: 30210832 DOI: 10.21037/jtd.2018.08.86] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
290 Kohli P, Staziaki PV, Janjua SA, Addison DA, Hallett TR, Hennessy O, Takx RAP, Lu MT, Fintelmann FJ, Semigran M, Harris RS, Celli BR, Hoffmann U, Neilan TG. The effect of emphysema on readmission and survival among smokers with heart failure. PLoS One 2018;13:e0201376. [PMID: 30059544 DOI: 10.1371/journal.pone.0201376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
291 van der Does AM, Amatngalim GD, Keijser B, Hiemstra PS, Villenave R. Contribution of Host Defence Proteins and Peptides to Host-Microbiota Interactions in Chronic Inflammatory Lung Diseases. Vaccines (Basel) 2018;6:E49. [PMID: 30060554 DOI: 10.3390/vaccines6030049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
292 Southworth T, Beech G, Foden P, Kolsum U, Singh D. The reproducibility of COPD blood eosinophil counts. Eur Respir J 2018;52:1800427. [PMID: 29724922 DOI: 10.1183/13993003.00427-2018] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 7.5] [Reference Citation Analysis]
293 Li Y, Feng J, Li Y, Jia W, Qian H. Assessment of a Domiciliary Integrated Pulmonary Rehabilitation Program for Patients with a History of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Retrospective 12-Month Observational Study. Med Sci Monit 2018;24:5054-63. [PMID: 30030421 DOI: 10.12659/MSM.908463] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
294 Jin M, Lee EC, Ra SW, Fishbane N, Tam S, Criner GJ, Woodruff PG, Lazarus SC, Albert R, Connett JE, Han MK, Martinez FJ, Aaron SD, Reed RM, Man SFP, Leung JM, Sin DD. Relationship of Absolute Telomere Length With Quality of Life, Exacerbations, and Mortality in COPD. Chest 2018;154:266-73. [PMID: 30017346 DOI: 10.1016/j.chest.2018.05.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
295 Citgez E, Zuur-telgen M, van der Palen J, van der Valk P, Stolz D, Brusse-keizer M. Stable-State Midrange Proadrenomedullin Is Associated With Severe Exacerbations in COPD. Chest 2018;154:51-7. [DOI: 10.1016/j.chest.2018.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
296 Strandkvist V, Andersson M, Backman H, Larsson A, Stridsman C, Lindberg A. Hand grip strength is associated with fatigue among men with COPD: epidemiological data from northern Sweden. Physiotherapy Theory and Practice 2020;36:408-16. [DOI: 10.1080/09593985.2018.1486490] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
297 Omer S. In matters of the heart, do not neglect the lungs: Influence of chronic obstructive pulmonary disease severity on outcomes after off-pump coronary artery bypass graft procedure. J Thorac Cardiovasc Surg 2018;156:1562-3. [PMID: 29935792 DOI: 10.1016/j.jtcvs.2018.05.016] [Reference Citation Analysis]
298 Hurst JR. Consolidation and Exacerbation of COPD. Med Sci (Basel) 2018;6:E44. [PMID: 29865214 DOI: 10.3390/medsci6020044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
299 Krakowiak K, Durrington HJ. The Role of the Body Clock in Asthma and COPD: Implication for Treatment. Pulm Ther 2018;4:29-43. [DOI: 10.1007/s41030-018-0058-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
300 Bourbeau J, Farias R. Making sense of telemedicine in the management of COPD. Eur Respir J 2018;51:1800851. [DOI: 10.1183/13993003.00851-2018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
301 Lázár Z, Kelemen Á, Gálffy G, Losonczy G, Horváth I, Bikov A. Central and peripheral airway nitric oxide in patients with stable and exacerbated chronic obstructive pulmonary disease. J Breath Res 2018;12:036017. [DOI: 10.1088/1752-7163/aac10a] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
302 Kania A, Krenke R, Kuziemski K, Czajkowska-Malinowska M, Celejewska-Wójcik N, Kuźnar-Kamińska B, Farnik M, Bokiej J, Miszczuk M, Damps-Konstańska I, Grabicki M, Trzaska-Sobczak M, Sładek K, Batura-Gabryel H, Barczyk A. Distribution and characteristics of COPD phenotypes - results from the Polish sub-cohort of the POPE study. Int J Chron Obstruct Pulmon Dis 2018;13:1613-21. [PMID: 29844667 DOI: 10.2147/COPD.S154716] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
303 Mendes MA, Chalmers JD. Predicting outcomes in bronchiectasis. Pulmonology 2018;24:146-8. [PMID: 29754718 DOI: 10.1016/j.pulmoe.2018.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
304 Lage SM, Britto RR, Brandão DC, Pereira DAG, Andrade AD, Parreira VF. Can diaphragmatic breathing modify chest wall volumes during inspiratory loaded breathing in patients with heart failure? Braz J Phys Ther 2018;22:452-8. [PMID: 29752160 DOI: 10.1016/j.bjpt.2018.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
305 Gawlitza J, Haubenreisser H, Henzler T, Akin I, Schönberg S, Borggrefe M, Trinkmann F. Finding the right spot: Where to measure airway parameters in patients with COPD. Eur J Radiol 2018;104:87-93. [PMID: 29857872 DOI: 10.1016/j.ejrad.2018.05.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
306 Schuler M, Strohmayer M, Mühlig S, Schwaighofer B, Wittmann M, Faller H, Schultz K. Assessment of depression before and after inpatient rehabilitation in COPD patients: Psychometric properties of the German version of the Patient Health Questionnaire (PHQ-9/PHQ-2). Journal of Affective Disorders 2018;232:268-75. [DOI: 10.1016/j.jad.2018.02.037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
307 Kim SK, Bae JC, Baek JH, Hur KY, Lee MK, Kim JH. Is decreased lung function associated with chronic kidney disease? A retrospective cohort study in Korea. BMJ Open 2018;8:e018928. [PMID: 29674361 DOI: 10.1136/bmjopen-2017-018928] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
308 Singh D, Barnes PJ, Stockley R, Lopez Valera MV, Vogelmeier C, Agusti A. Pharmacological treatment of COPD: the devil is always in the detail. Eur Respir J 2018;51:1800263. [PMID: 29674480 DOI: 10.1183/13993003.00263-2018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
309 Suarez-Barcelo M, Micca JL, Clackum S, Ferguson GT. Chronic obstructive pulmonary disease in the long-term care setting: current practices, challenges, and unmet needs. Curr Opin Pulm Med 2017;23 Suppl 1:S1-S28. [PMID: 28990958 DOI: 10.1097/MCP.0000000000000416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
310 Agusti A. The disease model: implications for clinical practice. Eur Respir J 2018;51:1800188. [PMID: 29650549 DOI: 10.1183/13993003.00188-2018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
311 Sun Y, Sin DD. Crisis of COPD in China: the future is now. Lancet Respir Med 2018;6:404-5. [PMID: 29650406 DOI: 10.1016/S2213-2600(18)30133-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
312 Durão V, Grafino M, Pamplona P. Chronic respiratory failure in patients with chronic obstructive pulmonary disease under home noninvasive ventilation: Real-life study. Pulmonology 2018;24:280-8. [PMID: 29628437 DOI: 10.1016/j.pulmoe.2018.02.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
313 Greulich T, Hohlfeld JM, Neuser P, Lueer K, Klemmer A, Schade-Brittinger C, Harnisch S, Garn H, Renz H, Homburg U, Renz J, Kirsten A, Pedersen F, Müller M, Vogelmeier CF, Watz H. A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial. Respir Res 2018;19:55. [PMID: 29615049 DOI: 10.1186/s12931-018-0751-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
314 Yi G, Liang M, Li M, Fang X, Liu J, Lai Y, Chen J, Yao W, Feng X, Hu L, Lin C, Zhou X, Liu Z. A large lung gene expression study identifying IL1B as a novel player in airway inflammation in COPD airway epithelial cells. Inflamm Res 2018;67:539-51. [DOI: 10.1007/s00011-018-1145-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
315 Roche N. Stable COPD Treatment: Where are We? COPD 2018;15:123-9. [PMID: 29608095 DOI: 10.1080/15412555.2018.1445214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
316 Chalmers JD. POINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV1 < 50% Predicted) COPD? Yes. Chest 2018;153:778-82. [DOI: 10.1016/j.chest.2018.01.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
317 Ramaswamy A, Puchalski J. Bronchoscopic lung volume reduction: recent updates. J Thorac Dis 2018;10:2519-27. [PMID: 29850160 DOI: 10.21037/jtd.2018.02.72] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
318 Vestbo J, Mathioudakis AG. The emerging Chinese COPD epidemic. The Lancet 2018;391:1642-3. [DOI: 10.1016/s0140-6736(18)30859-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
319 Bravo DM, Gimenes AC, Amorim BC, Alencar MC, Berton DC, O’donnell DE, Nery LE, Neder JA. Excess ventilation in COPD: Implications for dyspnoea and tolerance to interval exercise. Respiratory Physiology & Neurobiology 2018;250:7-13. [DOI: 10.1016/j.resp.2018.01.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
320 Smith LJ. The lower limit of normal versus a fixed ratio to assess airflow limitation: will the debate ever end? Eur Respir J 2018;51:1800403. [DOI: 10.1183/13993003.00403-2018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
321 Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study. Eur Respir J 2018;51:1702681. [PMID: 29449425 DOI: 10.1183/13993003.02681-2017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
322 Choi J, Oh JY, Lee YS, Min KH, Hur GY, Lee SY, Kang KH, Shim JJ. Harmful impact of air pollution on severe acute exacerbation of chronic obstructive pulmonary disease: particulate matter is hazardous. Int J Chron Obstruct Pulmon Dis 2018;13:1053-9. [PMID: 29681728 DOI: 10.2147/COPD.S156617] [Cited by in Crossref: 19] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
323 Higham A, Bostock D, Booth G, Dungwa JV, Singh D. The effect of electronic cigarette and tobacco smoke exposure on COPD bronchial epithelial cell inflammatory responses. Int J Chron Obstruct Pulmon Dis 2018;13:989-1000. [PMID: 29615835 DOI: 10.2147/COPD.S157728] [Cited by in Crossref: 27] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
324 Graumam RQ, Pinheiro MM, Nery LE, Castro CHM. Increased rate of osteoporosis, low lean mass, and fragility fractures in COPD patients: association with disease severity. Osteoporos Int 2018;29:1457-68. [PMID: 29564475 DOI: 10.1007/s00198-018-4483-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
325 McKeough Z, Cheng SWM, Alison J, Jenkins C, Hamer M, Stamatakis E. Low leisure-based sitting time and being physically active were associated with reduced odds of death and diabetes in people with chronic obstructive pulmonary disease: a cohort study. J Physiother 2018;64:114-20. [PMID: 29574168 DOI: 10.1016/j.jphys.2018.02.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
326 Li JX, Fu WP, Zhang J, Zhang XH, Sun C, Dai LM, Zhong L, Yu L, Zhang YP. A functional SNP upstream of the ADRB2 gene is associated with COPD. Int J Chron Obstruct Pulmon Dis 2018;13:917-25. [PMID: 29588580 DOI: 10.2147/COPD.S151153] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
327 Langer D, Ciavaglia C, Faisal A, Webb KA, Neder JA, Gosselink R, Dacha S, Topalovic M, Ivanova A, O'Donnell DE. Inspiratory muscle training reduces diaphragm activation and dyspnea during exercise in COPD. J Appl Physiol (1985) 2018;125:381-92. [PMID: 29543134 DOI: 10.1152/japplphysiol.01078.2017] [Cited by in Crossref: 45] [Cited by in F6Publishing: 57] [Article Influence: 11.3] [Reference Citation Analysis]
328 Viniol C, Vogelmeier CF. Exacerbations of COPD. Eur Respir Rev. 2018;27. [PMID: 29540496 DOI: 10.1183/16000617.0103-2017] [Cited by in Crossref: 77] [Cited by in F6Publishing: 106] [Article Influence: 19.3] [Reference Citation Analysis]
329 Andersson C, Bonvini SJ, Horvath P, Marquez E, Satia I, Kirkham P, Schleich F, Idzko M, Gosens R, Lopez-Campos JL, Bossios A, Usmani O, Spanevello A, Adcock IM, Mathioudakis AG. Research highlights from the 2017 ERS International Congress: airway diseases in focus. ERJ Open Res 2018;4:00163-2017. [PMID: 29546046 DOI: 10.1183/23120541.00163-2017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
330 Anzueto A, Miravitlles M. Considerations for the Correct Diagnosis of COPD and Its Management With Bronchodilators. Chest 2018;154:242-8. [PMID: 29524387 DOI: 10.1016/j.chest.2018.02.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
331 Yang M, Kohler M, Heyder T, Forsslund H, Garberg HK, Karimi R, Grunewald J, Berven FS, Nyrén S, Magnus Sköld C, Wheelock ÅM. Proteomic profiling of lung immune cells reveals dysregulation of phagocytotic pathways in female-dominated molecular COPD phenotype. Respir Res 2018;19:39. [PMID: 29514663 DOI: 10.1186/s12931-017-0699-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
332 Chalmers J, Aksamit T, Carvalho A, Rendon A, Franco I. Non-tuberculous mycobacterial pulmonary infections. Pulmonology 2018;24:120-31. [DOI: 10.1016/j.pulmoe.2017.12.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
333 Degani-Costa LH, O'Donnell DE, Webb K, Aranda LC, Carlstron JP, Cesar TDS, Plachi F, Berton DC, Neder JA, Nery LE. A Simplified Approach to Select Exercise Endurance Intensity for Interventional Studies in COPD. COPD 2018;15:139-47. [PMID: 29485343 DOI: 10.1080/15412555.2018.1428944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
334 Savran O, Ulrik CS. Early life insults as determinants of chronic obstructive pulmonary disease in adult life. Int J Chron Obstruct Pulmon Dis 2018;13:683-93. [PMID: 29520136 DOI: 10.2147/COPD.S153555] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 10.3] [Reference Citation Analysis]
335 Chalmers JD. Rebuttal From Dr Chalmers. Chest 2018;153:785-6. [PMID: 29474808 DOI: 10.1016/j.chest.2018.01.036] [Reference Citation Analysis]
336 Criner GJ. Revising our approach to conducting therapeutic clinical research in COPD. Eur Respir J 2018;51:1702712. [PMID: 29467209 DOI: 10.1183/13993003.02712-2017] [Reference Citation Analysis]
337 Halpin DMG. Palliative care for people with COPD: effective but underused. Eur Respir J 2018;51:1702645. [PMID: 29444923 DOI: 10.1183/13993003.02645-2017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
338 Sarmand N, Gompelmann D, Kontogianni K, Polke M, Herth FJ, Eberhardt R. New bacterial growth in bronchial secretions after bronchoscopic valve implantation. Int J Chron Obstruct Pulmon Dis 2018;13:565-70. [PMID: 29445273 DOI: 10.2147/COPD.S148196] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
339 Dharwal V, Naura AS. PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice. Biochem Pharmacol 2018;150:24-34. [PMID: 29355504 DOI: 10.1016/j.bcp.2018.01.027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
340 Jones R. The scale of the problem of obstructive lung disease in Africa becomes clearer, but where are the solutions? Eur Respir J 2018;51:1702562. [PMID: 29386341 DOI: 10.1183/13993003.02562-2017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
341 Zoller T, Mfinanga EH, Zumba TB, Asilia PJ, Mutabazi EM, Wimmersberger D, Kurth F, Mhimbira F, Haraka F, Reither K. Chronic airflow obstruction in Tanzania - a cross-sectional study. BMC Pulm Med 2018;18:11. [PMID: 29351754 DOI: 10.1186/s12890-018-0577-9] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
342 Alcázar-Navarrete B, Ruiz Rodríguez O, Conde Baena P, Romero Palacios PJ, Agusti A. Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. Eur Respir J 2018;51:1701457. [PMID: 29348180 DOI: 10.1183/13993003.01457-2017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
343 Ronit A, Lundgren J, Afzal S, Benfield T, Roen A, Mocroft A, Gerstoft J, Nordestgaard BG, Vestbo J, Nielsen SD. Airflow limitation in people living with HIV and matched uninfected controls. Thorax 2018;73:431-8. [DOI: 10.1136/thoraxjnl-2017-211079] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
344 Zelt JT, Jones JH, Hirai DM, King TJ, Berton DC, Pyke KE, O'Donnell DE, Neder JA. Systemic vascular dysfunction is associated with emphysema burden in mild COPD. Respir Med 2018;136:29-36. [PMID: 29501244 DOI: 10.1016/j.rmed.2018.01.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
345 de Vries R, Dagelet YWF, Spoor P, Snoey E, Jak PMC, Brinkman P, Dijkers E, Bootsma SK, Elskamp F, de Jongh FHC, Haarman EG, In 't Veen JCCM, Maitland-van der Zee AH, Sterk PJ. Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label. Eur Respir J 2018;51:1701817. [PMID: 29326334 DOI: 10.1183/13993003.01817-2017] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 16.5] [Reference Citation Analysis]
346 Li Y, Feng J, Li Y, Jia W, Qian H. A new pulmonary rehabilitation maintenance strategy through home-visiting and phone contact in COPD. Patient Prefer Adherence 2018;12:97-104. [PMID: 29391781 DOI: 10.2147/PPA.S150679] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
347 Vanfleteren LE, Ullman A, Fabbri LM. Time for a longer and better life for patients with COPD. Eur Respir J 2018;51:1702569. [DOI: 10.1183/13993003.02569-2017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
348 da Silva GP, Nascimento FA, Macêdo TP, Morano MT, Mesquita R, Pereira ED. Religious coping and religiosity in patients with COPD following pulmonary rehabilitation. Int J Chron Obstruct Pulmon Dis 2018;13:175-81. [PMID: 29379282 DOI: 10.2147/COPD.S146400] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
349 Faria-Urbina M, Oliveira RKF, Agarwal M, Waxman AB. Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease. Lung 2018;196:139-46. [PMID: 29275453 DOI: 10.1007/s00408-017-0081-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
350 De Smet EG, Seys LJ, Verhamme FM, Vanaudenaerde BM, Brusselle GG, Bingle CD, Bracke KR. Association of innate defense proteins BPIFA1 and BPIFB1 with disease severity in COPD. Int J Chron Obstruct Pulmon Dis 2018;13:11-27. [PMID: 29296079 DOI: 10.2147/COPD.S144136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
351 Lindberg A, Linder R, Backman H, Eriksson Ström J, Frølich A, Nilsson U, Rönmark E, Johansson Strandkvist V, Behndig AF, Blomberg A. From COPD epidemiology to studies of pathophysiological disease mechanisms: challenges with regard to study design and recruitment process: Respiratory and Cardiovascular Effects in COPD (KOLIN). Eur Clin Respir J 2017;4:1415095. [PMID: 29296255 DOI: 10.1080/20018525.2017.1415095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
352 Agustí A, Celli B. Natural history of COPD: gaps and opportunities. ERJ Open Res 2017;3:00117-2017. [PMID: 29255718 DOI: 10.1183/23120541.00117-2017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
353 Guillien A, Soumagne TE, Puyraveau M, Berger P, Guillot SL, Rannou F, Jouneau S, Mauny FJ, Laplante J, Dalphin J, Degano B. Case-Finding for Persistent Airway Obstruction in Farmers: A Questionnaire With Optimal Diagnosis Criteria. American Journal of Preventive Medicine 2017;53:837-44. [DOI: 10.1016/j.amepre.2017.06.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
354 Strassmann A, Frei A, Haile SR, ter Riet G, Puhan MA. Commonly Used Patient-Reported Outcomes Do Not Improve Prediction of COPD Exacerbations. Chest 2017;152:1179-87. [DOI: 10.1016/j.chest.2017.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
355 Bauer M, Fink B, Seyfarth HJ, Wirtz H, Frille A. Tobacco-smoking induced GPR15-expressing T cells in blood do not indicate pulmonary damage. BMC Pulm Med 2017;17:159. [PMID: 29183299 DOI: 10.1186/s12890-017-0509-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
356 Rabe KF, Beghé B, Fabbri LM. Peripheral eosinophil count as a biomarker for the management of COPD: not there yet. Eur Respir J 2017;50:1702165. [PMID: 29167308 DOI: 10.1183/13993003.02165-2017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
357 Tavazzi L. It's time to move on from counting co-morbidities to curing them: the case of chronic heart failure-chronic obstructive pulmonary disease co-morbidity. Eur J Heart Fail 2018;20:193-6. [PMID: 29164746 DOI: 10.1002/ejhf.1083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
358 Zhu K, Rabec C, Gonzalez-Bermejo J, Hardy S, Aouf S, Escourrou P, Roisman G. Combined effects of leaks, respiratory system properties and upper airway patency on the performance of home ventilators: a bench study. BMC Pulm Med 2017;17:145. [PMID: 29157220 DOI: 10.1186/s12890-017-0487-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
359 Cazzola M, Rogliani P, Puxeddu E, Ora J, Matera MG. An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? Expert Review of Respiratory Medicine 2018;12:43-54. [DOI: 10.1080/17476348.2018.1398086] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
360 Rocha NN, de Oliveira MV, Braga CL, Guimarães G, Maia LA, Padilha GA, Silva JD, Takiya CM, Capelozzi VL, Silva PL, Rocco PRM. Ghrelin therapy improves lung and cardiovascular function in experimental emphysema. Respir Res 2017;18:185. [PMID: 29100513 DOI: 10.1186/s12931-017-0668-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
361 Burgel PR, Paillasseur JL, Janssens W, Piquet J, Ter Riet G, Garcia-Aymerich J, Cosio B, Bakke P, Puhan MA, Langhammer A, Alfageme I, Almagro P, Ancochea J, Celli BR, Casanova C, de-Torres JP, Decramer M, Echazarreta A, Esteban C, Gomez Punter RM, Han MK, Johannessen A, Kaiser B, Lamprecht B, Lange P, Leivseth L, Marin JM, Martin F, Martinez-Camblor P, Miravitlles M, Oga T, Sofia Ramírez A, Sin DD, Sobradillo P, Soler-Cataluña JJ, Turner AM, Verdu Rivera FJ, Soriano JB, Roche N; Initiatives BPCO, EABPCO, Leuven and 3CIA study groups. A simple algorithm for the identification of clinical COPD phenotypes. Eur Respir J 2017;50:1701034. [PMID: 29097431 DOI: 10.1183/13993003.01034-2017] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
362 Faner R, Agustí A. COPD: algorithms and clinical management. Eur Respir J 2017;50:1701733. [PMID: 29097436 DOI: 10.1183/13993003.01733-2017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
363 Charron CE, Russell P, Ito K, Lea S, Kizawa Y, Brindley C, Singh D. RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation. Eur Respir J 2017;50:1700188. [PMID: 29074542 DOI: 10.1183/13993003.00188-2017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
364 Piazzolla G, Castrovilli A, Liotino V, Vulpi MR, Fanelli M, Mazzocca A, Candigliota M, Berardi E, Resta O, Sabbà C, Tortorella C. Metabolic syndrome and Chronic Obstructive Pulmonary Disease (COPD): The interplay among smoking, insulin resistance and vitamin D. PLoS One 2017;12:e0186708. [PMID: 29065130 DOI: 10.1371/journal.pone.0186708] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
365 Agustí A, Bafadhel M, Beasley R, Bel EH, Faner R, Gibson PG, Louis R, McDonald VM, Sterk PJ, Thomas M, Vogelmeier C, Pavord ID; on behalf of all participants in the seminar. Precision medicine in airway diseases: moving to clinical practice. Eur Respir J 2017;50:1701655. [PMID: 29051276 DOI: 10.1183/13993003.01655-2017] [Cited by in Crossref: 81] [Cited by in F6Publishing: 102] [Article Influence: 16.2] [Reference Citation Analysis]
366 Le Rouzic O, Roche N, Cortot AB, Tillie-Leblond I, Masure F, Perez T, Boucot I, Hamouti L, Ostinelli J, Pribil C, Poutchnine C, Schück S, Pouriel M, Housset B. Defining the "Frequent Exacerbator" Phenotype in COPD: A Hypothesis-Free Approach. Chest 2018;153:1106-15. [PMID: 29054347 DOI: 10.1016/j.chest.2017.10.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
367 Zysman M, Chabot F, Housset B, Morelot Panzini C, Devillier P, Roche N; Société de Pneumologie de Langue Française. Pharmacological treatment optimisation for stable COPD: an endless story? Proposals from the Société de Pneumologie de Langue Française. Eur Respir J 2017;50:1701250. [PMID: 29025880 DOI: 10.1183/13993003.01250-2017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
368 Dal Negro RW, Wedzicha JA, Iversen M, Fontana G, Page C, Cicero AF, Pozzi E, Calverley PMA; RESTORE group., RESTORE study. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J 2017;50:1700711. [PMID: 29025888 DOI: 10.1183/13993003.00711-2017] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
369 Conickx G, Avila Cobos F, van den Berge M, Faiz A, Timens W, Hiemstra PS, Joos GF, Brusselle GG, Mestdagh P, Bracke KR. microRNA profiling in lung tissue and bronchoalveolar lavage of cigarette smoke-exposed mice and in COPD patients: a translational approach. Sci Rep 2017;7:12871. [PMID: 28993685 DOI: 10.1038/s41598-017-13265-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
370 Ahmed E, Sansac C, Assou S, Gras D, Petit A, Vachier I, Chanez P, De Vos J, Bourdin A. Lung development, regeneration and plasticity: From disease physiopathology to drug design using induced pluripotent stem cells. Pharmacol Ther 2018;183:58-77. [PMID: 28987320 DOI: 10.1016/j.pharmthera.2017.10.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
371 Gutberlet M, Kaireit TF, Voskrebenzev A, Lasch F, Freise J, Welte T, Wacker F, Hohlfeld JM, Vogel-Claussen J. Free-breathing Dynamic 19F Gas MR Imaging for Mapping of Regional Lung Ventilation in Patients with COPD. Radiology 2018;286:1040-51. [PMID: 28972817 DOI: 10.1148/radiol.2017170591] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
372 Kreuter M, Cottin V. The threat in chronic lung diseases: acute exacerbations. Eur Respir Rev 2017;26:170075. [PMID: 28954770 DOI: 10.1183/16000617.0075-2017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
373 Ambrosino N, Fracchia C. The role of tele-medicine in patients with respiratory diseases. Expert Rev Respir Med 2017;11:893-900. [PMID: 28942692 DOI: 10.1080/17476348.2017.1383898] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
374 Canepa M, Straburzynska-Migaj E, Drozdz J, Fernandez-Vivancos C, Pinilla JMG, Nyolczas N, Temporelli PL, Mebazaa A, Lainscak M, Laroche C, Maggioni AP, Piepoli MF, Coats AJS, Ferrari R, Tavazzi L; ESC-HFA Heart Failure Long-Term Registry Investigators. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail 2018;20:100-10. [PMID: 28949063 DOI: 10.1002/ejhf.964] [Cited by in Crossref: 48] [Cited by in F6Publishing: 58] [Article Influence: 9.6] [Reference Citation Analysis]
375 Sethi GS, Dharwal V, Naura AS. Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review. Front Immunol 2017;8:1172. [PMID: 28974953 DOI: 10.3389/fimmu.2017.01172] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
376 Humbert M. Increasing confidence in the therapeutic relevance of eosinophils in severe asthma. Lancet Respir Med 2018;6:7-8. [PMID: 28919199 DOI: 10.1016/S2213-2600(17)30343-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
377 Keir HR, Fong CJ, Dicker AJ, Chalmers JD. Profile of the ProAxsis active neutrophil elastase immunoassay for precision medicine in chronic respiratory disease. Expert Review of Molecular Diagnostics 2017;17:875-84. [DOI: 10.1080/14737159.2017.1374174] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
378 Rossi A, Butorac-Petanjek B, Chilosi M, Cosío BG, Flezar M, Koulouris N, Marin J, Miculinic N, Polese G, Samaržija M, Skrgat S, Vassilakopoulos T, Vukić-Dugac A, Zakynthinos S, Miravitlles M. Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research - a consensus document from six scientific societies. Int J Chron Obstruct Pulmon Dis 2017;12:2593-610. [PMID: 28919728 DOI: 10.2147/COPD.S132236] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
379 Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J Chron Obstruct Pulmon Dis 2017;12:2545-58. [PMID: 28883722 DOI: 10.2147/COPD.S143488] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
380 Magnussen H, Canepa M, Zambito PE, Brusasco V, Meinertz T, Rosenkranz S. What can we learn from pulmonary function testing in heart failure?: Pulmonary function testing in heart failure. Eur J Heart Fail 2017;19:1222-9. [DOI: 10.1002/ejhf.946] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
381 Ma TT, Zhuang Y, Gong HY, Yii AC, Wang XY, Shi HZ. Predictive value of respiratory symptoms for the diagnosis of pollen-induced seasonal asthma among children and adults in Inner Mongolia. Ther Clin Risk Manag 2017;13:967-74. [PMID: 28831262 DOI: 10.2147/TCRM.S138355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
382 Thomas M, Halpin DM, Miravitlles M. When is dual bronchodilation indicated in COPD? Int J Chron Obstruct Pulmon Dis 2017;12:2291-305. [PMID: 28814857 DOI: 10.2147/COPD.S138554] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
383 van Boven JFM. Costly comorbidities of COPD: the ignored side of the coin? Eur Respir J 2017;50:1700917. [PMID: 28751418 DOI: 10.1183/13993003.00917-2017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
384 Pirina P, Martinetti M, Spada C, Zinellu E, Pes R, Chessa E, Fois AG, Miravitlles M; COPD-HF Study Group. Prevalence and management of COPD and heart failure comorbidity in the general practitioner setting. Respir Med 2017;131:1-5. [PMID: 28947013 DOI: 10.1016/j.rmed.2017.07.059] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
385 Calverley PM. Where to start when treating COPD?: Editorial. Respirology 2017;22:1239-40. [DOI: 10.1111/resp.13126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
386 Capozzolo A, Castellana G, Dragonieri S, Carratù P, Liotino V, Vulpi MR, Marra L, Resta E, Intiglietta P, Resta O. Voluntary lung function screening to reveal new COPD cases in southern Italy. Int J Chron Obstruct Pulmon Dis 2017;12:2035-42. [PMID: 28744118 DOI: 10.2147/COPD.S136357] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
387 Caram LMO, Ferrari R, Nogueira DL, Oliveira M, Francisqueti FV, Tanni SE, Corrêa CR, Godoy I. Tumor necrosis factor receptor 2 as a possible marker of COPD in smokers and ex-smokers. Int J Chron Obstruct Pulmon Dis 2017;12:2015-21. [PMID: 28744116 DOI: 10.2147/COPD.S138558] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
388 Mattila T, Vasankari T, Rissanen H, Knekt P, Puukka P, Heliövaara M. Airway obstruction and the risk of myocardial infarction and death from coronary heart disease: a national health examination survey with a 33-year follow-up period. Eur J Epidemiol 2018;33:89-98. [DOI: 10.1007/s10654-017-0278-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
389 Rodriguez-Roisin R, Rabe KF, Vestbo J, Vogelmeier C, Agustí A; all previous and current members of the Science Committee and the Board of Directors of GOLD (goldcopd.org/committees/). Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time. Eur Respir J 2017;50:1700671. [PMID: 28679615 DOI: 10.1183/13993003.00671-2017] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
390 Chung SM, Lee SY. Evaluation of Appropriate Management of Chronic Obstructive Pulmonary Disease in Korea: Based on Health Insurance Review and Assessment Service (HIRA) Claims. Tuberc Respir Dis (Seoul) 2017;80:241-6. [PMID: 28747956 DOI: 10.4046/trd.2017.80.3.241] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
391 Vestbo J, Woodcock A. Clinical trial research in focus: time to reflect on the design of exacerbation trials in COPD. The Lancet Respiratory Medicine 2017;5:466-8. [DOI: 10.1016/s2213-2600(17)30177-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
392 Singh D, D'Urzo AD, Chuecos F, Muñoz A, Garcia Gil E. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respir Res 2017;18:106. [PMID: 28558833 DOI: 10.1186/s12931-017-0583-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
393 Chalmers JD. Macrolide resistance in Pseudomonas aeruginosa: implications for practice. Eur Respir J 2017;49:1700689. [PMID: 28526802 DOI: 10.1183/13993003.00689-2017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
394 Roversi S, Corbetta L, Clini E. GOLD 2017 recommendations for COPD patients: toward a more personalized approach. COPD Res Pract 2017;3. [DOI: 10.1186/s40749-017-0024-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
395 Miravitlles M. Diagnosis of asthma-COPD overlap: the five commandments. Eur Respir J 2017;49:1700506. [PMID: 28461307 DOI: 10.1183/13993003.00506-2017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
396 Ambrosino N, Makhabah DN, Sutanto YS. Tele-medicine in respiratory diseases. Multidiscip Respir Med 2017;12:9. [PMID: 28435672 DOI: 10.1186/s40248-017-0090-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]